[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fJBiJXO720B1QAAYfSPCKwFZyBoUHTH0UJvpitZVv2B8":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":35,"phaseBuckets":84,"rows":91},"University Hospital, Rouen",[4],411,false,109,50,187959,45,292,[14,17,20,23,26,28,30,33],{"name":15,"count":16},"Irritable Bowel Syndrome",11,{"name":18,"count":19},"Anesthesia",8,{"name":21,"count":22},"Fecal Incontinence",7,{"name":24,"count":25},"Aortic Valve Stenosis",6,{"name":27,"count":25},"Obesity",{"name":29,"count":25},"Rheumatoid Arthritis",{"name":31,"count":32},"Surgery",5,{"name":34,"count":32},"Septic Shock",[36,41,46,51,56,61,65,70,75,80],{"nctId":37,"briefTitle":38,"date":39,"intervention":40},"NCT03611686","Observatory of Patients With Metastatic ProstAte Adenocarcinoma That is Resistant to Castration and Multi-LinE Strategies","2026-04","Local chemotherapy",{"nctId":42,"briefTitle":43,"date":44,"intervention":45},"NCT05708534","Evolution of CMV Antiviral T-cell Immunity Over the Next Six Months Initiation of Treatment With Belatacept.","2026-05-13","Belatacept",{"nctId":47,"briefTitle":48,"date":49,"intervention":50},"NCT04388124","Endothelin-1 Receptor Blockade in Resistant Hypertension","2026-08","Bosentan",{"nctId":52,"briefTitle":53,"date":54,"intervention":55},"NCT06559033","Determine the Frequency of Variants in the GBA\u002FPSAP Genes in Patients With MM or MGUS","2026-10-02","Evaluation of the presence and number of mutated alleles of the GBA\u002FPSAP genes in patients with MM or MGUS",{"nctId":57,"briefTitle":58,"date":59,"intervention":60},"NCT05708430","Tolerance of Intra-articular Injection Autologous Stromal Vascular Fraction for the Treatment of Rhizarthrosis","2026-12","SVF injection into wrist",{"nctId":62,"briefTitle":63,"date":59,"intervention":64},"NCT04227314","Randomized Double Blind Controlled Trial Comparing the Safety and Efficacy of Apremilast Versus Placebo in Severe Forms of Recurrent Aphthous Stomatitis","Apremilast",{"nctId":66,"briefTitle":67,"date":68,"intervention":69},"NCT05109936","Immediate Prescription of a Hypouricemic Treatment, Febuxostat, Compared to Its Delayed Administration","2027-01-01","Adenuric",{"nctId":71,"briefTitle":72,"date":73,"intervention":74},"NCT07332702","Long Read Analysis in Spinal Muscular Atrophy - LOREASI","2027-01-15","blood sample",{"nctId":76,"briefTitle":77,"date":78,"intervention":79},"NCT07039747","Effectiveness of a Dietary Supplement in Irritable Bowel Syndrome","2027-02","treatment with DIELEN® Protect",{"nctId":81,"briefTitle":82,"date":78,"intervention":83},"NCT05689463","Evaluation of the Prevalence of BP180 and BP230 Autoantibodies in the Serum of Patients With Pruritus Under Immunotherapy","characterisation of immunoglobulin subclasses",[85,86,87,88,89,90],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[92,130,200,225,243,268,293,318,336,361,386,411,438,456,480,506,524,545,571,589,614,640,658,676,701,722,748,774,792,813,837,855,876,894,914,937,963,981,1025,1051,1077,1095,1116,1139,1159,1185,1212,1230,1255,1283,1307,1331,1349,1375,1393,1417,1442,1470,1488,1514,1538,1564,1582,1600,1624,1660,1691,1717,1735,1753,1780,1798,1825,1843,1869,1896,1914,1932,1957,1983,2001,2019,2037,2062,2080,2104,2129,2147,2170,2188,2206,2224,2250,2268,2296,2314,2332,2357,2381,2404,2429,2456,2474,2492,2517,2540,2564,2582,2607,2625,2653,2671,2689,2707,2732,2759,2777,2802,2827,2851,2876,2894,2912,2967,3002,3035,3069,3102,3127,3152,3176,3199,3224,3249,3273,3296,3322,3346,3371,3399,3424,3449,3474,3492,3514,3532,3556,3581,3607,3625,3643,3671],{"intervention":45,"totalTrials":93,"cells":94},2,{"EARLY_PHASE1":95,"PHASE1":98,"PHASE2":100,"PHASE3":102,"PHASE4":104,"NA":119},{"trials":96,"activeCount":97},[],0,{"trials":99,"activeCount":97},[],{"trials":101,"activeCount":97},[],{"trials":103,"activeCount":97},[],{"trials":105,"activeCount":118,"soonestReadout":111},[106],{"nctId":107,"briefTitle":108,"status":109,"phases":110,"primaryCompletion":111,"completion":111,"start":112,"enrollment":113,"conditions":114,"interventions":116},"NCT06291077","Comparison of the Effects of Belatacept and Anticalcineurins on Endothelial Function in Renal Transplant Patients - \u003CBELAFENDO>","NOT_YET_RECRUITING",[89],"2028-12-01","2026-03-01",44,[115],"Kidney Diseases",[45,117],"anticalcineurins",1,{"trials":120,"activeCount":118,"soonestReadout":44},[121],{"nctId":42,"briefTitle":43,"status":122,"phases":123,"primaryCompletion":44,"completion":124,"start":125,"enrollment":126,"conditions":127,"interventions":129},"ACTIVE_NOT_RECRUITING",[],"2027-05-31","2023-11-14",28,[128],"Kidney Transplant Infection",[45],{"intervention":131,"totalTrials":32,"cells":132},"Rituximab",{"EARLY_PHASE1":133,"PHASE1":135,"PHASE2":137,"PHASE3":139,"PHASE4":175,"NA":198},{"trials":134,"activeCount":97},[],{"trials":136,"activeCount":97},[],{"trials":138,"activeCount":97},[],{"trials":140,"activeCount":97},[141,153,163],{"nctId":142,"briefTitle":143,"status":144,"phases":145,"primaryCompletion":146,"completion":146,"start":147,"enrollment":148,"conditions":149,"interventions":151},"NCT03790293","Clinical and Immunological Long-term Follow-up of Patients With Pemphigus Included in the \"RITUXIMAB 3\" Trial","COMPLETED",[88],"2019-04-19","2018-11-17",80,[150],"Autoimmune Diseases",[131,152],"corticosteroids'therapy",{"nctId":154,"briefTitle":155,"status":144,"phases":156,"primaryCompletion":157,"completion":158,"start":157,"enrollment":159,"conditions":160,"interventions":162},"NCT01299857","Long-term Clinical and Biological Evaluation of Patients With Severe Forms of Pemphigus Treated by Rituximab",[88],"2011-06","2012-06",22,[161],"Pemphigus",[131],{"nctId":164,"briefTitle":165,"status":144,"phases":166,"primaryCompletion":167,"completion":168,"start":169,"enrollment":170,"conditions":171,"interventions":173},"NCT00784589","Comparison Between Rituximab Treatment and General Corticotherapy Treatment in Patients With Pemphigus",[88],"2013-12","2016-12","2009-07",90,[172],"Pemphigus Disease",[174,131],"General Corticotherapy",{"trials":176,"activeCount":118,"soonestReadout":182},[177,189],{"nctId":178,"briefTitle":179,"status":180,"phases":181,"primaryCompletion":182,"completion":182,"start":183,"enrollment":184,"conditions":185,"interventions":187},"NCT05898308","Comparison of a Personalized Maintenance Therapy With the Standard Treatment in Pemphigus","RECRUITING",[89],"2032-05-01","2024-12-04",133,[161,186],"Dermatologic Disease",[188],"RiTUXimab",{"nctId":190,"briefTitle":191,"status":144,"phases":192,"primaryCompletion":193,"completion":193,"start":194,"enrollment":195,"conditions":196,"interventions":197},"NCT01765374","Study of Sonographic Efficacy of Rituximab in Rheumatoid Arthritis",[89],"2014-10","2011-02",30,[29],[131],{"trials":199,"activeCount":97},[],{"intervention":201,"totalTrials":118,"cells":202},"Nefopam administration and prelevment",{"EARLY_PHASE1":203,"PHASE1":205,"PHASE2":207,"PHASE3":209,"PHASE4":211,"NA":223},{"trials":204,"activeCount":97},[],{"trials":206,"activeCount":97},[],{"trials":208,"activeCount":97},[],{"trials":210,"activeCount":97},[],{"trials":212,"activeCount":118,"soonestReadout":217},[213],{"nctId":214,"briefTitle":215,"status":109,"phases":216,"primaryCompletion":217,"completion":217,"start":218,"enrollment":219,"conditions":220,"interventions":222},"NCT07491393","Pharmacokinetic Study of the Use of Nefopam 30 mg Tablets in Patients Suffering From Acute Pain in Rheumatology",[89],"2027-04-07","2026-04-01",24,[221],"Acute Rheumatic Pain",[201],{"trials":224,"activeCount":97},[],{"intervention":117,"totalTrials":118,"cells":226},{"EARLY_PHASE1":227,"PHASE1":229,"PHASE2":231,"PHASE3":233,"PHASE4":235,"NA":241},{"trials":228,"activeCount":97},[],{"trials":230,"activeCount":97},[],{"trials":232,"activeCount":97},[],{"trials":234,"activeCount":97},[],{"trials":236,"activeCount":118,"soonestReadout":111},[237],{"nctId":107,"briefTitle":108,"status":109,"phases":238,"primaryCompletion":111,"completion":111,"start":112,"enrollment":113,"conditions":239,"interventions":240},[89],[115],[45,117],{"trials":242,"activeCount":97},[],{"intervention":244,"totalTrials":118,"cells":245},"Domperidone 10mg",{"EARLY_PHASE1":246,"PHASE1":248,"PHASE2":250,"PHASE3":252,"PHASE4":264,"NA":266},{"trials":247,"activeCount":97},[],{"trials":249,"activeCount":97},[],{"trials":251,"activeCount":97},[],{"trials":253,"activeCount":118,"soonestReadout":258},[254],{"nctId":255,"briefTitle":256,"status":109,"phases":257,"primaryCompletion":258,"completion":259,"start":112,"enrollment":260,"conditions":261,"interventions":263},"NCT06695962","Efficacy of Domperidone (a Prokinetic Agent) on Time in Range in Digestively Asymptomatic Type I Diabetic Patients With Delayed Gastric Emptying (Gastro-TIR)",[88],"2029-06-01","2029-07-01",70,[262],"Type 1 Diabetic",[244],{"trials":265,"activeCount":97},[],{"trials":267,"activeCount":97},[],{"intervention":269,"totalTrials":118,"cells":270},"Naropeine",{"EARLY_PHASE1":271,"PHASE1":273,"PHASE2":275,"PHASE3":277,"PHASE4":289,"NA":291},{"trials":272,"activeCount":97},[],{"trials":274,"activeCount":97},[],{"trials":276,"activeCount":97},[],{"trials":278,"activeCount":118,"soonestReadout":283},[279],{"nctId":280,"briefTitle":281,"status":180,"phases":282,"primaryCompletion":283,"completion":283,"start":284,"enrollment":285,"conditions":286,"interventions":288},"NCT05969457","Effect of Preventive Analgesia by Injection of a Local Anesthetic Before Vaginal Incision for Hysterectomy by vNOTES Approach",[88],"2029-09-01","2025-09-16",108,[287],"Hysterotomy; Affecting Fetus",[269],{"trials":290,"activeCount":97},[],{"trials":292,"activeCount":97},[],{"intervention":294,"totalTrials":118,"cells":295},"Conversion to Belatacep",{"EARLY_PHASE1":296,"PHASE1":298,"PHASE2":300,"PHASE3":302,"PHASE4":314,"NA":316},{"trials":297,"activeCount":97},[],{"trials":299,"activeCount":97},[],{"trials":301,"activeCount":97},[],{"trials":303,"activeCount":118,"soonestReadout":308},[304],{"nctId":305,"briefTitle":306,"status":109,"phases":307,"primaryCompletion":308,"completion":308,"start":112,"enrollment":309,"conditions":310,"interventions":312},"NCT06291103","Screening for Subclinical Antibody Mediated Rejection and Efficacy of Belatacept in the Context of de Novo Donor Specific Antibody After Kidney Transplantation (BELA-M-R)",[87,88],"2032-04-01",290,[311],"Kidney Transplant Rejection",[294,313],"Standard of care treatment (SOC regimen) with Tacrolimus",{"trials":315,"activeCount":97},[],{"trials":317,"activeCount":97},[],{"intervention":313,"totalTrials":118,"cells":319},{"EARLY_PHASE1":320,"PHASE1":322,"PHASE2":324,"PHASE3":326,"PHASE4":332,"NA":334},{"trials":321,"activeCount":97},[],{"trials":323,"activeCount":97},[],{"trials":325,"activeCount":97},[],{"trials":327,"activeCount":118,"soonestReadout":308},[328],{"nctId":305,"briefTitle":306,"status":109,"phases":329,"primaryCompletion":308,"completion":308,"start":112,"enrollment":309,"conditions":330,"interventions":331},[87,88],[311],[294,313],{"trials":333,"activeCount":97},[],{"trials":335,"activeCount":97},[],{"intervention":337,"totalTrials":118,"cells":338},"Neoadjuvant chemotherapy",{"EARLY_PHASE1":339,"PHASE1":341,"PHASE2":343,"PHASE3":345,"PHASE4":357,"NA":359},{"trials":340,"activeCount":97},[],{"trials":342,"activeCount":97},[],{"trials":344,"activeCount":97},[],{"trials":346,"activeCount":118,"soonestReadout":351},[347],{"nctId":348,"briefTitle":349,"status":180,"phases":350,"primaryCompletion":351,"completion":351,"start":352,"enrollment":353,"conditions":354,"interventions":356},"NCT06107920","Neoadjuvant Chemotherapy for Obstructive Colon cancER First Treated by cOlostomy",[88],"2031-08","2024-05-07",232,[355],"Colon Cancer",[337],{"trials":358,"activeCount":97},[],{"trials":360,"activeCount":97},[],{"intervention":362,"totalTrials":118,"cells":363},"intra-rectal botulinum toxin injections",{"EARLY_PHASE1":364,"PHASE1":366,"PHASE2":368,"PHASE3":370,"PHASE4":382,"NA":384},{"trials":365,"activeCount":97},[],{"trials":367,"activeCount":97},[],{"trials":369,"activeCount":97},[],{"trials":371,"activeCount":118,"soonestReadout":376},[372],{"nctId":373,"briefTitle":374,"status":180,"phases":375,"primaryCompletion":376,"completion":377,"start":378,"enrollment":379,"conditions":380,"interventions":381},"NCT05998187","Mechanisms of Action on Rectal Motricity of Intrarectal Botulinum Toxin Injections",[88],"2027-06-01","2027-12-01","2025-04-15",21,[21],[362],{"trials":383,"activeCount":97},[],{"trials":385,"activeCount":97},[],{"intervention":387,"totalTrials":118,"cells":388},"Baricitinib 4 MG",{"EARLY_PHASE1":389,"PHASE1":391,"PHASE2":393,"PHASE3":395,"PHASE4":407,"NA":409},{"trials":390,"activeCount":97},[],{"trials":392,"activeCount":97},[],{"trials":394,"activeCount":97},[],{"trials":396,"activeCount":118,"soonestReadout":401},[397],{"nctId":398,"briefTitle":399,"status":109,"phases":400,"primaryCompletion":401,"completion":401,"start":402,"enrollment":403,"conditions":404,"interventions":406},"NCT05651880","Efficacy and Tolerance of Baricitinib, a JAK Inhibitor, in the Treatment of Refractory Non-infectious Non-anterior Uveitis",[88],"2029-08","2026-03",33,[405],"Active Non-anterior Non-infectious Uveitis",[387],{"trials":408,"activeCount":97},[],{"trials":410,"activeCount":97},[],{"intervention":412,"totalTrials":118,"cells":413},"Gem\u002FNabpaclitaxel",{"EARLY_PHASE1":414,"PHASE1":416,"PHASE2":418,"PHASE3":420,"PHASE4":434,"NA":436},{"trials":415,"activeCount":97},[],{"trials":417,"activeCount":97},[],{"trials":419,"activeCount":97},[],{"trials":421,"activeCount":118,"soonestReadout":426},[422],{"nctId":423,"briefTitle":424,"status":180,"phases":425,"primaryCompletion":426,"completion":427,"start":428,"enrollment":429,"conditions":430,"interventions":432},"NCT07044453","Risk-adapted Adjuvant Chemotherapy Guided by the Tumour Stage for Operated Pancreatic Adenocarcinoma Following Neoadjuvant Chemotherapy With mFOLFIRINOX",[87,88],"2030-09","2032-09","2025-12-08",390,[431],"Resected Pancreatic Adenocarcinoma",[412,433],"mFOLFIRINOX",{"trials":435,"activeCount":97},[],{"trials":437,"activeCount":97},[],{"intervention":433,"totalTrials":118,"cells":439},{"EARLY_PHASE1":440,"PHASE1":442,"PHASE2":444,"PHASE3":446,"PHASE4":452,"NA":454},{"trials":441,"activeCount":97},[],{"trials":443,"activeCount":97},[],{"trials":445,"activeCount":97},[],{"trials":447,"activeCount":118,"soonestReadout":426},[448],{"nctId":423,"briefTitle":424,"status":180,"phases":449,"primaryCompletion":426,"completion":427,"start":428,"enrollment":429,"conditions":450,"interventions":451},[87,88],[431],[412,433],{"trials":453,"activeCount":97},[],{"trials":455,"activeCount":97},[],{"intervention":457,"totalTrials":118,"cells":458},"ROVALCYTE",{"EARLY_PHASE1":459,"PHASE1":461,"PHASE2":463,"PHASE3":465,"PHASE4":476,"NA":478},{"trials":460,"activeCount":97},[],{"trials":462,"activeCount":97},[],{"trials":464,"activeCount":97},[],{"trials":466,"activeCount":118,"soonestReadout":471},[467],{"nctId":468,"briefTitle":469,"status":180,"phases":470,"primaryCompletion":471,"completion":471,"start":472,"enrollment":473,"conditions":474,"interventions":475},"NCT05708508","Effectiveness of an Immune-guided Cytomegalovirus Infection Preventive Strategy Compared to a Universal Prophylactic Strategy in Renal Transplant Patients",[88],"2027-04","2024-03-28",144,[128],[457],{"trials":477,"activeCount":97},[],{"trials":479,"activeCount":97},[],{"intervention":481,"totalTrials":118,"cells":482},"Rituximab 1g IV",{"EARLY_PHASE1":483,"PHASE1":485,"PHASE2":487,"PHASE3":489,"PHASE4":502,"NA":504},{"trials":484,"activeCount":97},[],{"trials":486,"activeCount":97},[],{"trials":488,"activeCount":97},[],{"trials":490,"activeCount":118,"soonestReadout":495},[491],{"nctId":492,"briefTitle":493,"status":180,"phases":494,"primaryCompletion":495,"completion":495,"start":496,"enrollment":497,"conditions":498,"interventions":500},"NCT03295383","Randomized Clinical Trial Comparing the Safety and Efficacy of Rituximab Versus Oral Cyclophosphamide in Severe Forms of Mucous Membrane Pemphigoid",[88],"2027-03","2019-07-11",130,[499],"Severe Forms of Mucous Membrane Pemphigoid",[481,501],"Cyclophosphamide 50Mg Oral",{"trials":503,"activeCount":97},[],{"trials":505,"activeCount":97},[],{"intervention":501,"totalTrials":118,"cells":507},{"EARLY_PHASE1":508,"PHASE1":510,"PHASE2":512,"PHASE3":514,"PHASE4":520,"NA":522},{"trials":509,"activeCount":97},[],{"trials":511,"activeCount":97},[],{"trials":513,"activeCount":97},[],{"trials":515,"activeCount":118,"soonestReadout":495},[516],{"nctId":492,"briefTitle":493,"status":180,"phases":517,"primaryCompletion":495,"completion":495,"start":496,"enrollment":497,"conditions":518,"interventions":519},[88],[499],[481,501],{"trials":521,"activeCount":97},[],{"trials":523,"activeCount":97},[],{"intervention":69,"totalTrials":118,"cells":525},{"EARLY_PHASE1":526,"PHASE1":528,"PHASE2":530,"PHASE3":532,"PHASE4":541,"NA":543},{"trials":527,"activeCount":97},[],{"trials":529,"activeCount":97},[],{"trials":531,"activeCount":97},[],{"trials":533,"activeCount":118,"soonestReadout":68},[534],{"nctId":66,"briefTitle":67,"status":180,"phases":535,"primaryCompletion":68,"completion":68,"start":536,"enrollment":537,"conditions":538,"interventions":540},[88],"2023-08-02",128,[539],"Gout",[69],{"trials":542,"activeCount":97},[],{"trials":544,"activeCount":97},[],{"intervention":546,"totalTrials":118,"cells":547},"Antibioprophylaxis",{"EARLY_PHASE1":548,"PHASE1":550,"PHASE2":552,"PHASE3":554,"PHASE4":567,"NA":569},{"trials":549,"activeCount":97},[],{"trials":551,"activeCount":97},[],{"trials":553,"activeCount":97},[],{"trials":555,"activeCount":118,"soonestReadout":560},[556],{"nctId":557,"briefTitle":558,"status":109,"phases":559,"primaryCompletion":560,"completion":560,"start":39,"enrollment":561,"conditions":562,"interventions":565},"NCT06123169","Postoperative Anti-infective Strategy Following Pancreaticoduodenectomy in Patients With Preoperative Biliary Stent",[88],"2028-07",326,[563,564],"Pancreaticoduodenectomy","Antibiotherapy",[546,566],"5 days Antibiotherapy",{"trials":568,"activeCount":97},[],{"trials":570,"activeCount":97},[],{"intervention":566,"totalTrials":118,"cells":572},{"EARLY_PHASE1":573,"PHASE1":575,"PHASE2":577,"PHASE3":579,"PHASE4":585,"NA":587},{"trials":574,"activeCount":97},[],{"trials":576,"activeCount":97},[],{"trials":578,"activeCount":97},[],{"trials":580,"activeCount":118,"soonestReadout":560},[581],{"nctId":557,"briefTitle":558,"status":109,"phases":582,"primaryCompletion":560,"completion":560,"start":39,"enrollment":561,"conditions":583,"interventions":584},[88],[563,564],[546,566],{"trials":586,"activeCount":97},[],{"trials":588,"activeCount":97},[],{"intervention":590,"totalTrials":118,"cells":591},"Sildenafil",{"EARLY_PHASE1":592,"PHASE1":594,"PHASE2":596,"PHASE3":598,"PHASE4":610,"NA":612},{"trials":593,"activeCount":97},[],{"trials":595,"activeCount":97},[],{"trials":597,"activeCount":97},[],{"trials":599,"activeCount":118,"soonestReadout":604},[600],{"nctId":601,"briefTitle":602,"status":180,"phases":603,"primaryCompletion":604,"completion":604,"start":605,"enrollment":606,"conditions":607,"interventions":609},"NCT06123156","Interest of Early Erectile Rehabilitation With Sildenafil After Radiotherapy and Proctectomy for Rectal Cancer",[88],"2030-02","2025-09-25",188,[608],"Rectal Cancer",[590],{"trials":611,"activeCount":97},[],{"trials":613,"activeCount":97},[],{"intervention":615,"totalTrials":118,"cells":616},"aspirin intake",{"EARLY_PHASE1":617,"PHASE1":619,"PHASE2":621,"PHASE3":623,"PHASE4":636,"NA":638},{"trials":618,"activeCount":97},[],{"trials":620,"activeCount":97},[],{"trials":622,"activeCount":97},[],{"trials":624,"activeCount":118,"soonestReadout":560},[625],{"nctId":626,"briefTitle":627,"status":180,"phases":628,"primaryCompletion":560,"completion":560,"start":629,"enrollment":630,"conditions":631,"interventions":633},"NCT02945033","Study on Aspirin Versus Placebo in Resected Colon Cancer With PI3K Mutation Stage III or II High Risk",[88],"2018-07-12",264,[632],"Colorectal Cancer",[615,634,635],"Molecular analysis of exon 9 and 20 of PI3K","blood intake",{"trials":637,"activeCount":97},[],{"trials":639,"activeCount":97},[],{"intervention":634,"totalTrials":118,"cells":641},{"EARLY_PHASE1":642,"PHASE1":644,"PHASE2":646,"PHASE3":648,"PHASE4":654,"NA":656},{"trials":643,"activeCount":97},[],{"trials":645,"activeCount":97},[],{"trials":647,"activeCount":97},[],{"trials":649,"activeCount":118,"soonestReadout":560},[650],{"nctId":626,"briefTitle":627,"status":180,"phases":651,"primaryCompletion":560,"completion":560,"start":629,"enrollment":630,"conditions":652,"interventions":653},[88],[632],[615,634,635],{"trials":655,"activeCount":97},[],{"trials":657,"activeCount":97},[],{"intervention":635,"totalTrials":118,"cells":659},{"EARLY_PHASE1":660,"PHASE1":662,"PHASE2":664,"PHASE3":666,"PHASE4":672,"NA":674},{"trials":661,"activeCount":97},[],{"trials":663,"activeCount":97},[],{"trials":665,"activeCount":97},[],{"trials":667,"activeCount":118,"soonestReadout":560},[668],{"nctId":626,"briefTitle":627,"status":180,"phases":669,"primaryCompletion":560,"completion":560,"start":629,"enrollment":630,"conditions":670,"interventions":671},[88],[632],[615,634,635],{"trials":673,"activeCount":97},[],{"trials":675,"activeCount":97},[],{"intervention":677,"totalTrials":118,"cells":678},"Iloprost",{"EARLY_PHASE1":679,"PHASE1":681,"PHASE2":683,"PHASE3":685,"PHASE4":697,"NA":699},{"trials":680,"activeCount":97},[],{"trials":682,"activeCount":97},[],{"trials":684,"activeCount":97},[],{"trials":686,"activeCount":118,"soonestReadout":691},[687],{"nctId":688,"briefTitle":689,"status":109,"phases":690,"primaryCompletion":691,"completion":691,"start":692,"enrollment":473,"conditions":693,"interventions":696},"NCT07498309","Evaluation of the Efficacy of Iloprost in the Management of Vaso-occlusive Crises in Adult Patients With Sickle Cell Disease",[88],"2030-03","2026-09",[694,695],"Vaso-Occlusive Crises","Sickle Cell Disease",[677],{"trials":698,"activeCount":97},[],{"trials":700,"activeCount":97},[],{"intervention":64,"totalTrials":118,"cells":702},{"EARLY_PHASE1":703,"PHASE1":705,"PHASE2":707,"PHASE3":709,"PHASE4":718,"NA":720},{"trials":704,"activeCount":97},[],{"trials":706,"activeCount":97},[],{"trials":708,"activeCount":97},[],{"trials":710,"activeCount":118,"soonestReadout":59},[711],{"nctId":62,"briefTitle":63,"status":180,"phases":712,"primaryCompletion":59,"completion":59,"start":713,"enrollment":714,"conditions":715,"interventions":717},[88],"2022-04-10",134,[716],"Recurrent Aphtous Stomatitis",[64],{"trials":719,"activeCount":97},[],{"trials":721,"activeCount":97},[],{"intervention":723,"totalTrials":118,"cells":724},"Fosfomycun-trometamol",{"EARLY_PHASE1":725,"PHASE1":727,"PHASE2":729,"PHASE3":731,"PHASE4":744,"NA":746},{"trials":726,"activeCount":97},[],{"trials":728,"activeCount":97},[],{"trials":730,"activeCount":97},[],{"trials":732,"activeCount":118,"soonestReadout":737},[733],{"nctId":734,"briefTitle":735,"status":109,"phases":736,"primaryCompletion":737,"completion":737,"start":402,"enrollment":738,"conditions":739,"interventions":743},"NCT06822751","FOsfomycin for Male Urinary Tract Infection",[88],"2029-06",138,[740,741,742],"Urinary Tract Infection","Prostatitis","Cystitis",[723],{"trials":745,"activeCount":97},[],{"trials":747,"activeCount":97},[],{"intervention":749,"totalTrials":118,"cells":750},"treatment adaptation guided by ctDNA variation",{"EARLY_PHASE1":751,"PHASE1":753,"PHASE2":755,"PHASE3":757,"PHASE4":770,"NA":772},{"trials":752,"activeCount":97},[],{"trials":754,"activeCount":97},[],{"trials":756,"activeCount":97},[],{"trials":758,"activeCount":118,"soonestReadout":763},[759],{"nctId":760,"briefTitle":761,"status":109,"phases":762,"primaryCompletion":763,"completion":763,"start":764,"enrollment":765,"conditions":766,"interventions":768},"NCT06446557","De-scalation or swItch of Treatment According to Circulating tuMOr DNA Variation After 2 Cycles of Doublet Chemotherapy Plus Targeted Agent in Metastatic Unresectable Colorectal Cancer",[88],"2032-06-01","2026-06",408,[767],"Metastatic Colon Cancer",[749,769],"standard management",{"trials":771,"activeCount":97},[],{"trials":773,"activeCount":97},[],{"intervention":769,"totalTrials":118,"cells":775},{"EARLY_PHASE1":776,"PHASE1":778,"PHASE2":780,"PHASE3":782,"PHASE4":788,"NA":790},{"trials":777,"activeCount":97},[],{"trials":779,"activeCount":97},[],{"trials":781,"activeCount":97},[],{"trials":783,"activeCount":118,"soonestReadout":763},[784],{"nctId":760,"briefTitle":761,"status":109,"phases":785,"primaryCompletion":763,"completion":763,"start":764,"enrollment":765,"conditions":786,"interventions":787},[88],[767],[749,769],{"trials":789,"activeCount":97},[],{"trials":791,"activeCount":97},[],{"intervention":60,"totalTrials":118,"cells":793},{"EARLY_PHASE1":794,"PHASE1":796,"PHASE2":798,"PHASE3":807,"PHASE4":809,"NA":811},{"trials":795,"activeCount":97},[],{"trials":797,"activeCount":97},[],{"trials":799,"activeCount":118,"soonestReadout":59},[800],{"nctId":57,"briefTitle":58,"status":180,"phases":801,"primaryCompletion":59,"completion":59,"start":802,"enrollment":803,"conditions":804,"interventions":806},[87],"2024-02-15",12,[805],"Rhizarthrosis",[60],{"trials":808,"activeCount":97},[],{"trials":810,"activeCount":97},[],{"trials":812,"activeCount":97},[],{"intervention":814,"totalTrials":118,"cells":815},"standard care + rotigotine at 4 mg\u002F24h for 24 months.",{"EARLY_PHASE1":816,"PHASE1":818,"PHASE2":820,"PHASE3":831,"PHASE4":833,"NA":835},{"trials":817,"activeCount":97},[],{"trials":819,"activeCount":97},[],{"trials":821,"activeCount":118,"soonestReadout":826},[822],{"nctId":823,"briefTitle":824,"status":109,"phases":825,"primaryCompletion":826,"completion":826,"start":112,"enrollment":827,"conditions":828,"interventions":829},"NCT06291116","Safety of RotigotiNe in Patients With Autosomal Dominant Polycystic Kidney Disease",[87],"2030-05-01",120,[115],[814,830],"standard care for 24 months.",{"trials":832,"activeCount":97},[],{"trials":834,"activeCount":97},[],{"trials":836,"activeCount":97},[],{"intervention":830,"totalTrials":118,"cells":838},{"EARLY_PHASE1":839,"PHASE1":841,"PHASE2":843,"PHASE3":849,"PHASE4":851,"NA":853},{"trials":840,"activeCount":97},[],{"trials":842,"activeCount":97},[],{"trials":844,"activeCount":118,"soonestReadout":826},[845],{"nctId":823,"briefTitle":824,"status":109,"phases":846,"primaryCompletion":826,"completion":826,"start":112,"enrollment":827,"conditions":847,"interventions":848},[87],[115],[814,830],{"trials":850,"activeCount":97},[],{"trials":852,"activeCount":97},[],{"trials":854,"activeCount":97},[],{"intervention":79,"totalTrials":118,"cells":856},{"EARLY_PHASE1":857,"PHASE1":859,"PHASE2":861,"PHASE3":870,"PHASE4":872,"NA":874},{"trials":858,"activeCount":97},[],{"trials":860,"activeCount":97},[],{"trials":862,"activeCount":118,"soonestReadout":78},[863],{"nctId":76,"briefTitle":77,"status":180,"phases":864,"primaryCompletion":78,"completion":78,"start":865,"enrollment":866,"conditions":867,"interventions":868},[87],"2025-04-22",100,[15],[79,869],"treatment with placebo of DIELEN® Protect",{"trials":871,"activeCount":97},[],{"trials":873,"activeCount":97},[],{"trials":875,"activeCount":97},[],{"intervention":869,"totalTrials":118,"cells":877},{"EARLY_PHASE1":878,"PHASE1":880,"PHASE2":882,"PHASE3":888,"PHASE4":890,"NA":892},{"trials":879,"activeCount":97},[],{"trials":881,"activeCount":97},[],{"trials":883,"activeCount":118,"soonestReadout":78},[884],{"nctId":76,"briefTitle":77,"status":180,"phases":885,"primaryCompletion":78,"completion":78,"start":865,"enrollment":866,"conditions":886,"interventions":887},[87],[15],[79,869],{"trials":889,"activeCount":97},[],{"trials":891,"activeCount":97},[],{"trials":893,"activeCount":97},[],{"intervention":50,"totalTrials":118,"cells":895},{"EARLY_PHASE1":896,"PHASE1":898,"PHASE2":900,"PHASE3":908,"PHASE4":910,"NA":912},{"trials":897,"activeCount":97},[],{"trials":899,"activeCount":97},[],{"trials":901,"activeCount":118,"soonestReadout":49},[902],{"nctId":47,"briefTitle":48,"status":180,"phases":903,"primaryCompletion":49,"completion":49,"start":904,"enrollment":219,"conditions":905,"interventions":907},[87],"2021-10-20",[906],"Resistant Hypertension",[50],{"trials":909,"activeCount":97},[],{"trials":911,"activeCount":97},[],{"trials":913,"activeCount":97},[],{"intervention":915,"totalTrials":118,"cells":916},"Aprepitant 125 and 80Mg Oral",{"EARLY_PHASE1":917,"PHASE1":919,"PHASE2":921,"PHASE3":931,"PHASE4":933,"NA":935},{"trials":918,"activeCount":97},[],{"trials":920,"activeCount":97},[],{"trials":922,"activeCount":118,"soonestReadout":376},[923],{"nctId":924,"briefTitle":925,"status":180,"phases":926,"primaryCompletion":376,"completion":376,"start":927,"enrollment":219,"conditions":928,"interventions":930},"NCT06462287","EFFECT OF A SUBSTANCE P ANTAGONIST ON THE SECRETION OF ALDOSTERONE IN PATIENTS WITH OBSTRUCTIVE SLEEP APNEA SYNDROME AND ARTERIAL HYPERTENSION",[87],"2024-03-05",[929],"Apnea, Obstructive",[915],{"trials":932,"activeCount":97},[],{"trials":934,"activeCount":97},[],{"trials":936,"activeCount":97},[],{"intervention":938,"totalTrials":118,"cells":939},"Fentanyl - Inhalation by facial nebulization",{"EARLY_PHASE1":940,"PHASE1":942,"PHASE2":955,"PHASE3":957,"PHASE4":959,"NA":961},{"trials":941,"activeCount":97},[],{"trials":943,"activeCount":118,"soonestReadout":376},[944],{"nctId":945,"briefTitle":946,"status":180,"phases":947,"primaryCompletion":376,"completion":376,"start":948,"enrollment":949,"conditions":950,"interventions":953},"NCT06281951","Nebulized Fentanyl in Healthy Volunteers",[86],"2024-04-26",20,[951,952],"Analgesia","Emergencies",[938,954],"Fentanyl - Nebulisation",{"trials":956,"activeCount":97},[],{"trials":958,"activeCount":97},[],{"trials":960,"activeCount":97},[],{"trials":962,"activeCount":97},[],{"intervention":954,"totalTrials":118,"cells":964},{"EARLY_PHASE1":965,"PHASE1":967,"PHASE2":973,"PHASE3":975,"PHASE4":977,"NA":979},{"trials":966,"activeCount":97},[],{"trials":968,"activeCount":118,"soonestReadout":376},[969],{"nctId":945,"briefTitle":946,"status":180,"phases":970,"primaryCompletion":376,"completion":376,"start":948,"enrollment":949,"conditions":971,"interventions":972},[86],[951,952],[938,954],{"trials":974,"activeCount":97},[],{"trials":976,"activeCount":97},[],{"trials":978,"activeCount":97},[],{"trials":980,"activeCount":97},[],{"intervention":74,"totalTrials":982,"cells":983},3,{"EARLY_PHASE1":984,"PHASE1":986,"PHASE2":988,"PHASE3":990,"PHASE4":1005,"NA":1007},{"trials":985,"activeCount":97},[],{"trials":987,"activeCount":97},[],{"trials":989,"activeCount":97},[],{"trials":991,"activeCount":97},[992],{"nctId":993,"briefTitle":994,"status":995,"phases":996,"primaryCompletion":997,"completion":997,"start":998,"enrollment":827,"conditions":999,"interventions":1001},"NCT00290082","Randomized Double-blind Trial of Midazolam and Loxapine in Agitated Patients","TERMINATED",[88],"2007-10","2005-12",[1000],"Acute Agitated Patients",[1002,74,1003,1004],"loxapine, midazolam","Loxapine","Midazolam",{"trials":1006,"activeCount":97},[],{"trials":1008,"activeCount":118,"soonestReadout":73},[1009,1018],{"nctId":1010,"briefTitle":1011,"status":995,"phases":1012,"primaryCompletion":1013,"completion":1013,"start":1014,"enrollment":25,"conditions":1015,"interventions":1017},"NCT03846128","Impact of Sunitinib Bioavailability on Toxicity and Treatment Efficacy in Patients Treated for Metastatic Renal Cancer",[],"2021-10-08","2019-06-03",[1016],"Metastatic Kidney Cancer",[74],{"nctId":71,"briefTitle":72,"status":180,"phases":1019,"primaryCompletion":73,"completion":73,"start":1020,"enrollment":1021,"conditions":1022,"interventions":1024},[90],"2025-05-15",27,[1023],"Spinal Muscular Atrophy (SMA)",[74],{"intervention":1026,"totalTrials":118,"cells":1027},"RNA and\u002For DNA methylation and\u002For protein analysis",{"EARLY_PHASE1":1028,"PHASE1":1030,"PHASE2":1032,"PHASE3":1034,"PHASE4":1036,"NA":1038},{"trials":1029,"activeCount":97},[],{"trials":1031,"activeCount":97},[],{"trials":1033,"activeCount":97},[],{"trials":1035,"activeCount":97},[],{"trials":1037,"activeCount":97},[],{"trials":1039,"activeCount":118,"soonestReadout":1044},[1040],{"nctId":1041,"briefTitle":1042,"status":180,"phases":1043,"primaryCompletion":1044,"completion":1045,"start":1046,"enrollment":1047,"conditions":1048,"interventions":1050},"NCT06955624","Use of Omics Methods to Classify Variations of Uncertain Significance and Improve Diagnosis of Neurogenetic Diseases",[90],"2030-01-15","2031-01-15","2025-01-15",95,[1049],"Neurogenetic Diseases",[1026],{"intervention":1052,"totalTrials":118,"cells":1053},"urine intestinal permeability test or lactulose\u002Fmannitol test",{"EARLY_PHASE1":1054,"PHASE1":1056,"PHASE2":1058,"PHASE3":1060,"PHASE4":1062,"NA":1064},{"trials":1055,"activeCount":97},[],{"trials":1057,"activeCount":97},[],{"trials":1059,"activeCount":97},[],{"trials":1061,"activeCount":97},[],{"trials":1063,"activeCount":97},[],{"trials":1065,"activeCount":118,"soonestReadout":1070},[1066],{"nctId":1067,"briefTitle":1068,"status":109,"phases":1069,"primaryCompletion":1070,"completion":1070,"start":1071,"enrollment":1072,"conditions":1073,"interventions":1075},"NCT07337707","New Microbiota-endocrine Axis in Fructose Malabsorption-caused Visceral Hypersensitivity in Irritable Bowel Syndrome.",[90],"2027-08","2026-02",60,[1074],"Irritable Bowel Syndrome (IBS)",[1052,1076],"Blood test",{"intervention":1076,"totalTrials":118,"cells":1078},{"EARLY_PHASE1":1079,"PHASE1":1081,"PHASE2":1083,"PHASE3":1085,"PHASE4":1087,"NA":1089},{"trials":1080,"activeCount":97},[],{"trials":1082,"activeCount":97},[],{"trials":1084,"activeCount":97},[],{"trials":1086,"activeCount":97},[],{"trials":1088,"activeCount":97},[],{"trials":1090,"activeCount":118,"soonestReadout":1070},[1091],{"nctId":1067,"briefTitle":1068,"status":109,"phases":1092,"primaryCompletion":1070,"completion":1070,"start":1071,"enrollment":1072,"conditions":1093,"interventions":1094},[90],[1074],[1052,1076],{"intervention":40,"totalTrials":118,"cells":1096},{"EARLY_PHASE1":1097,"PHASE1":1099,"PHASE2":1101,"PHASE3":1103,"PHASE4":1105,"NA":1107},{"trials":1098,"activeCount":97},[],{"trials":1100,"activeCount":97},[],{"trials":1102,"activeCount":97},[],{"trials":1104,"activeCount":97},[],{"trials":1106,"activeCount":97},[],{"trials":1108,"activeCount":118,"soonestReadout":39},[1109],{"nctId":37,"briefTitle":38,"status":122,"phases":1110,"primaryCompletion":39,"completion":39,"start":1111,"enrollment":1112,"conditions":1113,"interventions":1115},[],"2018-04-17",219,[1114],"Metastatic Prostate Adenocarcinoma",[40],{"intervention":55,"totalTrials":118,"cells":1117},{"EARLY_PHASE1":1118,"PHASE1":1120,"PHASE2":1122,"PHASE3":1124,"PHASE4":1126,"NA":1128},{"trials":1119,"activeCount":97},[],{"trials":1121,"activeCount":97},[],{"trials":1123,"activeCount":97},[],{"trials":1125,"activeCount":97},[],{"trials":1127,"activeCount":97},[],{"trials":1129,"activeCount":118,"soonestReadout":54},[1130],{"nctId":52,"briefTitle":53,"status":109,"phases":1131,"primaryCompletion":54,"completion":1132,"start":1133,"enrollment":1134,"conditions":1135,"interventions":1138},[],"2027-04-01","2025-06-01",300,[1136,1137],"Monoclonal Gammopathy of Undetermined Significance","Myeloma Multiple",[55],{"intervention":83,"totalTrials":118,"cells":1140},{"EARLY_PHASE1":1141,"PHASE1":1143,"PHASE2":1145,"PHASE3":1147,"PHASE4":1149,"NA":1151},{"trials":1142,"activeCount":97},[],{"trials":1144,"activeCount":97},[],{"trials":1146,"activeCount":97},[],{"trials":1148,"activeCount":97},[],{"trials":1150,"activeCount":97},[],{"trials":1152,"activeCount":118,"soonestReadout":78},[1153],{"nctId":81,"briefTitle":82,"status":180,"phases":1154,"primaryCompletion":78,"completion":78,"start":1155,"enrollment":866,"conditions":1156,"interventions":1158},[90],"2023-02-23",[1157],"Patients With Chronic Pruritus for More Than 1 Month Who Have Received Immunotherapy",[83],{"intervention":1160,"totalTrials":118,"cells":1161},"Dosage concentration of piperacillin and tazobactam",{"EARLY_PHASE1":1162,"PHASE1":1164,"PHASE2":1166,"PHASE3":1168,"PHASE4":1170,"NA":1172},{"trials":1163,"activeCount":97},[],{"trials":1165,"activeCount":97},[],{"trials":1167,"activeCount":97},[],{"trials":1169,"activeCount":97},[],{"trials":1171,"activeCount":97},[],{"trials":1173,"activeCount":118,"soonestReadout":1178},[1174],{"nctId":1175,"briefTitle":1176,"status":109,"phases":1177,"primaryCompletion":1178,"completion":1179,"start":1180,"enrollment":219,"conditions":1181,"interventions":1184},"NCT07167524","Evaluation of the Dialytic Clearance of the Combination of Peracillin and Tazobactam",[],"2027-10-01","2028-04-01","2025-10-01",[1182,1183],"Sepsis","Severe Bacterial Infections",[1160],{"intervention":1186,"totalTrials":118,"cells":1187},"gastrograffin",{"EARLY_PHASE1":1188,"PHASE1":1190,"PHASE2":1192,"PHASE3":1194,"PHASE4":1196,"NA":1210},{"trials":1189,"activeCount":97},[],{"trials":1191,"activeCount":97},[],{"trials":1193,"activeCount":97},[],{"trials":1195,"activeCount":97},[],{"trials":1197,"activeCount":97},[1198],{"nctId":1199,"briefTitle":1200,"status":144,"phases":1201,"primaryCompletion":1202,"completion":1203,"start":1204,"enrollment":1205,"conditions":1206,"interventions":1208},"NCT00389116","Value of CT-Scan and Oral Gastrografin in the Management of Post Operative Small Bowel Obstruction",[89],"2009-08","2010-08","2006-11",242,[1207],"Small Bowel Obstruction",[1186,1209],"water",{"trials":1211,"activeCount":97},[],{"intervention":1209,"totalTrials":118,"cells":1213},{"EARLY_PHASE1":1214,"PHASE1":1216,"PHASE2":1218,"PHASE3":1220,"PHASE4":1222,"NA":1228},{"trials":1215,"activeCount":97},[],{"trials":1217,"activeCount":97},[],{"trials":1219,"activeCount":97},[],{"trials":1221,"activeCount":97},[],{"trials":1223,"activeCount":97},[1224],{"nctId":1199,"briefTitle":1200,"status":144,"phases":1225,"primaryCompletion":1202,"completion":1203,"start":1204,"enrollment":1205,"conditions":1226,"interventions":1227},[89],[1207],[1186,1209],{"trials":1229,"activeCount":97},[],{"intervention":1231,"totalTrials":118,"cells":1232},"Bevacizumab in combination with chemotherapy based on fluoropyrimidine IV",{"EARLY_PHASE1":1233,"PHASE1":1235,"PHASE2":1237,"PHASE3":1239,"PHASE4":1241,"NA":1253},{"trials":1234,"activeCount":97},[],{"trials":1236,"activeCount":97},[],{"trials":1238,"activeCount":97},[],{"trials":1240,"activeCount":97},[],{"trials":1242,"activeCount":97},[1243],{"nctId":1244,"briefTitle":1245,"status":144,"phases":1246,"primaryCompletion":1247,"completion":1247,"start":1248,"enrollment":1249,"conditions":1250,"interventions":1252},"NCT04813913","VASCular Impact of Angiogenic Treatment in Patients With Advanced Colorectal Cancer",[89],"2022-07-21","2019-05-05",13,[1251],"Oncology",[1231],{"trials":1254,"activeCount":97},[],{"intervention":1256,"totalTrials":118,"cells":1257},"magnesium",{"EARLY_PHASE1":1258,"PHASE1":1260,"PHASE2":1262,"PHASE3":1264,"PHASE4":1266,"NA":1281},{"trials":1259,"activeCount":97},[],{"trials":1261,"activeCount":97},[],{"trials":1263,"activeCount":97},[],{"trials":1265,"activeCount":97},[],{"trials":1267,"activeCount":97},[1268],{"nctId":1269,"briefTitle":1270,"status":144,"phases":1271,"completion":1272,"start":1273,"enrollment":1274,"conditions":1275,"interventions":1280},"NCT00120588","Neuroprotection by Magnesium Sulfate Given to Women at Risk of Very Preterm Birth",[89],"2005-07","1997-07",700,[1276,1277,1278,1279],"Preterm Birth","Periventricular Leukomalacia","Brain Ischemia","Intracranial Hemorrhages",[1256],{"trials":1282,"activeCount":97},[],{"intervention":1284,"totalTrials":118,"cells":1285},"anti drug antibodies dosage",{"EARLY_PHASE1":1286,"PHASE1":1288,"PHASE2":1290,"PHASE3":1292,"PHASE4":1294,"NA":1305},{"trials":1287,"activeCount":97},[],{"trials":1289,"activeCount":97},[],{"trials":1291,"activeCount":97},[],{"trials":1293,"activeCount":97},[],{"trials":1295,"activeCount":97},[1296],{"nctId":1297,"briefTitle":1298,"status":995,"phases":1299,"primaryCompletion":1300,"completion":1300,"start":1301,"enrollment":19,"conditions":1302,"interventions":1304},"NCT01971918","Comparative Analysis of Two Therapeutic Strategies in Patients With Spondyloarthritis Treated With Anti-tnf Biologics",[89],"2017-04","2014-05",[1303],"Spondyloarthritis",[1284],{"trials":1306,"activeCount":97},[],{"intervention":1308,"totalTrials":118,"cells":1309},"Prolonged sedation with isoflurane",{"EARLY_PHASE1":1310,"PHASE1":1312,"PHASE2":1314,"PHASE3":1316,"PHASE4":1318,"NA":1329},{"trials":1311,"activeCount":97},[],{"trials":1313,"activeCount":97},[],{"trials":1315,"activeCount":97},[],{"trials":1317,"activeCount":97},[],{"trials":1319,"activeCount":97},[1320],{"nctId":1321,"briefTitle":1322,"status":995,"phases":1323,"primaryCompletion":1324,"completion":1324,"start":1325,"enrollment":118,"conditions":1326,"interventions":1327},"NCT04710914","Comparison of Extubation Delay After Prolonged Sedation",[89],"2020-12-26","2020-12-15",[34],[1308,1328],"Prolonged sedation with midazolam",{"trials":1330,"activeCount":97},[],{"intervention":1328,"totalTrials":118,"cells":1332},{"EARLY_PHASE1":1333,"PHASE1":1335,"PHASE2":1337,"PHASE3":1339,"PHASE4":1341,"NA":1347},{"trials":1334,"activeCount":97},[],{"trials":1336,"activeCount":97},[],{"trials":1338,"activeCount":97},[],{"trials":1340,"activeCount":97},[],{"trials":1342,"activeCount":97},[1343],{"nctId":1321,"briefTitle":1322,"status":995,"phases":1344,"primaryCompletion":1324,"completion":1324,"start":1325,"enrollment":118,"conditions":1345,"interventions":1346},[89],[34],[1308,1328],{"trials":1348,"activeCount":97},[],{"intervention":1350,"totalTrials":118,"cells":1351},"Serratus plane block and paravertebral block",{"EARLY_PHASE1":1352,"PHASE1":1354,"PHASE2":1356,"PHASE3":1358,"PHASE4":1360,"NA":1373},{"trials":1353,"activeCount":97},[],{"trials":1355,"activeCount":97},[],{"trials":1357,"activeCount":97},[],{"trials":1359,"activeCount":97},[],{"trials":1361,"activeCount":97},[1362],{"nctId":1363,"briefTitle":1364,"status":144,"phases":1365,"primaryCompletion":1366,"completion":1366,"start":1367,"enrollment":1368,"conditions":1369,"interventions":1371},"NCT03852862","Double Regional Anesthesia in Video Assisted Thoracoscopy",[89],"2020-11-10","2019-05-08",112,[1370,18],"Video Assisted Thoracoscopy",[1350,1372],"paravertebral block",{"trials":1374,"activeCount":97},[],{"intervention":1372,"totalTrials":118,"cells":1376},{"EARLY_PHASE1":1377,"PHASE1":1379,"PHASE2":1381,"PHASE3":1383,"PHASE4":1385,"NA":1391},{"trials":1378,"activeCount":97},[],{"trials":1380,"activeCount":97},[],{"trials":1382,"activeCount":97},[],{"trials":1384,"activeCount":97},[],{"trials":1386,"activeCount":97},[1387],{"nctId":1363,"briefTitle":1364,"status":144,"phases":1388,"primaryCompletion":1366,"completion":1366,"start":1367,"enrollment":1368,"conditions":1389,"interventions":1390},[89],[1370,18],[1350,1372],{"trials":1392,"activeCount":97},[],{"intervention":1394,"totalTrials":118,"cells":1395},"Clobetasol Propionate cream treatment",{"EARLY_PHASE1":1396,"PHASE1":1398,"PHASE2":1400,"PHASE3":1402,"PHASE4":1404,"NA":1415},{"trials":1397,"activeCount":97},[],{"trials":1399,"activeCount":97},[],{"trials":1401,"activeCount":97},[],{"trials":1403,"activeCount":97},[],{"trials":1405,"activeCount":97},[1406],{"nctId":1407,"briefTitle":1408,"status":144,"phases":1409,"primaryCompletion":1410,"completion":1410,"start":1411,"enrollment":195,"conditions":1412,"interventions":1414},"NCT02360202","Evaluation of Fluid Retention Due to Superpotent Topical Corticosteroid",[89],"2017-02-28","2015-02-17",[1413],"Bullous Pemphigoid",[1394],{"trials":1416,"activeCount":97},[],{"intervention":1418,"totalTrials":118,"cells":1419},"aprepitant\u002Fplacebo",{"EARLY_PHASE1":1420,"PHASE1":1422,"PHASE2":1424,"PHASE3":1426,"PHASE4":1428,"NA":1440},{"trials":1421,"activeCount":97},[],{"trials":1423,"activeCount":97},[],{"trials":1425,"activeCount":97},[],{"trials":1427,"activeCount":97},[],{"trials":1429,"activeCount":97},[1430],{"nctId":1431,"briefTitle":1432,"status":144,"phases":1433,"primaryCompletion":1434,"completion":1435,"start":1436,"enrollment":949,"conditions":1437,"interventions":1439},"NCT00977223","Effects of Substance P Antagonists on Adrenal Secretion",[89],"2010-04","2010-06","2009-06",[1438],"Healthy Volunteers",[1418],{"trials":1441,"activeCount":97},[],{"intervention":1443,"totalTrials":118,"cells":1444},"propofol",{"EARLY_PHASE1":1445,"PHASE1":1447,"PHASE2":1449,"PHASE3":1451,"PHASE4":1453,"NA":1468},{"trials":1446,"activeCount":97},[],{"trials":1448,"activeCount":97},[],{"trials":1450,"activeCount":97},[],{"trials":1452,"activeCount":97},[],{"trials":1454,"activeCount":97},[1455],{"nctId":1456,"briefTitle":1457,"status":144,"phases":1458,"primaryCompletion":1459,"completion":1459,"start":1460,"enrollment":1461,"conditions":1462,"interventions":1466},"NCT02272166","Effects of Propofol on Early Recovery of Hunger After Surgery",[89],"2016-07","2014-11",116,[1463,18,1464,1465],"Ambulatory Surgery","Energy Expenditure","Food Intake",[1443,1467],"Sevoflurane",{"trials":1469,"activeCount":97},[],{"intervention":1467,"totalTrials":118,"cells":1471},{"EARLY_PHASE1":1472,"PHASE1":1474,"PHASE2":1476,"PHASE3":1478,"PHASE4":1480,"NA":1486},{"trials":1473,"activeCount":97},[],{"trials":1475,"activeCount":97},[],{"trials":1477,"activeCount":97},[],{"trials":1479,"activeCount":97},[],{"trials":1481,"activeCount":97},[1482],{"nctId":1456,"briefTitle":1457,"status":144,"phases":1483,"primaryCompletion":1459,"completion":1459,"start":1460,"enrollment":1461,"conditions":1484,"interventions":1485},[89],[1463,18,1464,1465],[1443,1467],{"trials":1487,"activeCount":97},[],{"intervention":1489,"totalTrials":118,"cells":1490},"Basophil Activation Test",{"EARLY_PHASE1":1491,"PHASE1":1493,"PHASE2":1495,"PHASE3":1497,"PHASE4":1499,"NA":1512},{"trials":1492,"activeCount":97},[],{"trials":1494,"activeCount":97},[],{"trials":1496,"activeCount":97},[],{"trials":1498,"activeCount":97},[],{"trials":1500,"activeCount":97},[1501],{"nctId":1502,"briefTitle":1503,"status":144,"phases":1504,"primaryCompletion":1505,"completion":1505,"start":1506,"enrollment":1507,"conditions":1508,"interventions":1511},"NCT01966640","Basophil Activation Test (BAT) Sensitivity in Child Food Allergy",[89],"2019-01-11","2013-09-12",140,[1509,1510],"Allergy to Egg","Allergy to Peanut",[1489],{"trials":1513,"activeCount":97},[],{"intervention":1515,"totalTrials":118,"cells":1516},"ropivacaine",{"EARLY_PHASE1":1517,"PHASE1":1519,"PHASE2":1521,"PHASE3":1523,"PHASE4":1525,"NA":1536},{"trials":1518,"activeCount":97},[],{"trials":1520,"activeCount":97},[],{"trials":1522,"activeCount":97},[],{"trials":1524,"activeCount":97},[],{"trials":1526,"activeCount":97},[1527],{"nctId":1528,"briefTitle":1529,"status":995,"phases":1530,"primaryCompletion":1531,"completion":1531,"start":158,"enrollment":1532,"conditions":1533,"interventions":1535},"NCT01686347","Epidural Analgesia and Troubles of Fetal Cardiaq Rythm : Effect of the Systemic Transfer of Ropivacaine and Sufentanil",[89],"2015-12",40,[1534],"Fetal Cardiac Rhythm Abnormalities",[1515],{"trials":1537,"activeCount":97},[],{"intervention":1539,"totalTrials":118,"cells":1540},"cinacalcet",{"EARLY_PHASE1":1541,"PHASE1":1543,"PHASE2":1545,"PHASE3":1547,"PHASE4":1549,"NA":1562},{"trials":1542,"activeCount":97},[],{"trials":1544,"activeCount":97},[],{"trials":1546,"activeCount":97},[],{"trials":1548,"activeCount":97},[],{"trials":1550,"activeCount":97},[1551],{"nctId":1552,"briefTitle":1553,"status":144,"phases":1554,"primaryCompletion":1555,"completion":1555,"start":1434,"enrollment":1556,"conditions":1557,"interventions":1559},"NCT01103206","Evaluation of a Cincalcet Suppression Test",[89],"2013-02",36,[1558],"Parathyroid Hormone Suppression Test With Cinacalcet",[1539,1560,1561],"cinacalcet dose 1","cinacalcet dose 2",{"trials":1563,"activeCount":97},[],{"intervention":1560,"totalTrials":118,"cells":1565},{"EARLY_PHASE1":1566,"PHASE1":1568,"PHASE2":1570,"PHASE3":1572,"PHASE4":1574,"NA":1580},{"trials":1567,"activeCount":97},[],{"trials":1569,"activeCount":97},[],{"trials":1571,"activeCount":97},[],{"trials":1573,"activeCount":97},[],{"trials":1575,"activeCount":97},[1576],{"nctId":1552,"briefTitle":1553,"status":144,"phases":1577,"primaryCompletion":1555,"completion":1555,"start":1434,"enrollment":1556,"conditions":1578,"interventions":1579},[89],[1558],[1539,1560,1561],{"trials":1581,"activeCount":97},[],{"intervention":1561,"totalTrials":118,"cells":1583},{"EARLY_PHASE1":1584,"PHASE1":1586,"PHASE2":1588,"PHASE3":1590,"PHASE4":1592,"NA":1598},{"trials":1585,"activeCount":97},[],{"trials":1587,"activeCount":97},[],{"trials":1589,"activeCount":97},[],{"trials":1591,"activeCount":97},[],{"trials":1593,"activeCount":97},[1594],{"nctId":1552,"briefTitle":1553,"status":144,"phases":1595,"primaryCompletion":1555,"completion":1555,"start":1434,"enrollment":1556,"conditions":1596,"interventions":1597},[89],[1558],[1539,1560,1561],{"trials":1599,"activeCount":97},[],{"intervention":1601,"totalTrials":118,"cells":1602},"Adalimumab",{"EARLY_PHASE1":1603,"PHASE1":1605,"PHASE2":1607,"PHASE3":1609,"PHASE4":1611,"NA":1622},{"trials":1604,"activeCount":97},[],{"trials":1606,"activeCount":97},[],{"trials":1608,"activeCount":97},[],{"trials":1610,"activeCount":97},[],{"trials":1612,"activeCount":97},[1613],{"nctId":1614,"briefTitle":1615,"status":144,"phases":1616,"primaryCompletion":1617,"completion":1617,"start":1618,"enrollment":1619,"conditions":1620,"interventions":1621},"NCT00234234","Predictors of the Response to Adalimumab in Rheumatoid Arthritis",[89],"2008-12","2006-01",200,[29],[1601],{"trials":1623,"activeCount":97},[],{"intervention":1625,"totalTrials":93,"cells":1626},"Remifentanil",{"EARLY_PHASE1":1627,"PHASE1":1629,"PHASE2":1631,"PHASE3":1644,"PHASE4":1656,"NA":1658},{"trials":1628,"activeCount":97},[],{"trials":1630,"activeCount":97},[],{"trials":1632,"activeCount":97},[1633],{"nctId":1634,"briefTitle":1635,"status":144,"phases":1636,"primaryCompletion":1637,"completion":1637,"start":1638,"enrollment":1639,"conditions":1640,"interventions":1642},"NCT02029898","Remifentanil for General Anesthesia in the Context of Immaturity",[86,87],"2018-06-22","2014-02-02",53,[1641,18],"Cesarean Section",[1625,1643],"sodium chloride 0,9%",{"trials":1645,"activeCount":97},[1646],{"nctId":1647,"briefTitle":1648,"status":144,"phases":1649,"primaryCompletion":1650,"completion":1650,"start":1651,"enrollment":1652,"conditions":1653,"interventions":1654},"NCT04940689","Opioid-Free Anesthesia in Cardiac Surgery",[88],"2024-08-28","2021-07-22",268,[18],[1655,1625],"Dexmédétomidine 0.5 g\u002Fkg + lidocaine 1.5 mg\u002Fkg",{"trials":1657,"activeCount":97},[],{"trials":1659,"activeCount":97},[],{"intervention":1661,"totalTrials":93,"cells":1662},"Mabthera",{"EARLY_PHASE1":1663,"PHASE1":1665,"PHASE2":1667,"PHASE3":1669,"PHASE4":1687,"NA":1689},{"trials":1664,"activeCount":97},[],{"trials":1666,"activeCount":97},[],{"trials":1668,"activeCount":97},[],{"trials":1670,"activeCount":97},[1671,1680],{"nctId":1672,"briefTitle":1673,"status":144,"phases":1674,"primaryCompletion":1675,"completion":1676,"start":1677,"enrollment":159,"conditions":1678,"interventions":1679},"NCT00213512","Effect of Anti CD20 in Pemphigus Desease",[87,88],"2006-06","2008-10","2003-06",[161],[1661],{"nctId":1681,"briefTitle":1682,"status":144,"phases":1683,"primaryCompletion":167,"completion":167,"start":1617,"enrollment":1684,"conditions":1685,"interventions":1686},"NCT00525616","Efficiency and Tolerance of Rituximab (mabthéra) in Bullous Pemphigoid",[88],18,[1413],[1661],{"trials":1688,"activeCount":97},[],{"trials":1690,"activeCount":97},[],{"intervention":1692,"totalTrials":118,"cells":1693},"20 mL topically used during alginate dressing NAROPEINE",{"EARLY_PHASE1":1694,"PHASE1":1696,"PHASE2":1698,"PHASE3":1700,"PHASE4":1713,"NA":1715},{"trials":1695,"activeCount":97},[],{"trials":1697,"activeCount":97},[],{"trials":1699,"activeCount":97},[],{"trials":1701,"activeCount":97},[1702],{"nctId":1703,"briefTitle":1704,"status":144,"phases":1705,"primaryCompletion":1706,"completion":1706,"start":1707,"enrollment":1708,"conditions":1709,"interventions":1711},"NCT01999153","Evaluation of the Analgesic Effect of Ropivacaine in Topical Use at the Thin Skin Graft Donor Site",[88],"2018-10-04","2013-12-09",58,[1710],"Graft Pain",[1692,1712],"20 mL topically used during alginate dressing NaCl",{"trials":1714,"activeCount":97},[],{"trials":1716,"activeCount":97},[],{"intervention":1712,"totalTrials":118,"cells":1718},{"EARLY_PHASE1":1719,"PHASE1":1721,"PHASE2":1723,"PHASE3":1725,"PHASE4":1731,"NA":1733},{"trials":1720,"activeCount":97},[],{"trials":1722,"activeCount":97},[],{"trials":1724,"activeCount":97},[],{"trials":1726,"activeCount":97},[1727],{"nctId":1703,"briefTitle":1704,"status":144,"phases":1728,"primaryCompletion":1706,"completion":1706,"start":1707,"enrollment":1708,"conditions":1729,"interventions":1730},[88],[1710],[1692,1712],{"trials":1732,"activeCount":97},[],{"trials":1734,"activeCount":97},[],{"intervention":152,"totalTrials":118,"cells":1736},{"EARLY_PHASE1":1737,"PHASE1":1739,"PHASE2":1741,"PHASE3":1743,"PHASE4":1749,"NA":1751},{"trials":1738,"activeCount":97},[],{"trials":1740,"activeCount":97},[],{"trials":1742,"activeCount":97},[],{"trials":1744,"activeCount":97},[1745],{"nctId":142,"briefTitle":143,"status":144,"phases":1746,"primaryCompletion":146,"completion":146,"start":147,"enrollment":148,"conditions":1747,"interventions":1748},[88],[150],[131,152],{"trials":1750,"activeCount":97},[],{"trials":1752,"activeCount":97},[],{"intervention":1754,"totalTrials":118,"cells":1755},"ivabradine",{"EARLY_PHASE1":1756,"PHASE1":1758,"PHASE2":1760,"PHASE3":1762,"PHASE4":1776,"NA":1778},{"trials":1757,"activeCount":97},[],{"trials":1759,"activeCount":97},[],{"trials":1761,"activeCount":97},[],{"trials":1763,"activeCount":97},[1764],{"nctId":1765,"briefTitle":1766,"status":144,"phases":1767,"primaryCompletion":1768,"completion":1768,"start":1769,"enrollment":949,"conditions":1770,"interventions":1774},"NCT02584439","Effect of Pharmacological Heart Rate Reduction on Visco-elastic Properties of the Arterial Wall (BRADYVASC)",[88],"2019-07-15","2015-12-03",[1771,1772,1773],"Healthy","Vascular Stiffness","Aging",[1754,1775],"lactose",{"trials":1777,"activeCount":97},[],{"trials":1779,"activeCount":97},[],{"intervention":1775,"totalTrials":118,"cells":1781},{"EARLY_PHASE1":1782,"PHASE1":1784,"PHASE2":1786,"PHASE3":1788,"PHASE4":1794,"NA":1796},{"trials":1783,"activeCount":97},[],{"trials":1785,"activeCount":97},[],{"trials":1787,"activeCount":97},[],{"trials":1789,"activeCount":97},[1790],{"nctId":1765,"briefTitle":1766,"status":144,"phases":1791,"primaryCompletion":1768,"completion":1768,"start":1769,"enrollment":949,"conditions":1792,"interventions":1793},[88],[1771,1772,1773],[1754,1775],{"trials":1795,"activeCount":97},[],{"trials":1797,"activeCount":97},[],{"intervention":1799,"totalTrials":118,"cells":1800},"Ferinject 1000 mg",{"EARLY_PHASE1":1801,"PHASE1":1803,"PHASE2":1805,"PHASE3":1807,"PHASE4":1821,"NA":1823},{"trials":1802,"activeCount":97},[],{"trials":1804,"activeCount":97},[],{"trials":1806,"activeCount":97},[],{"trials":1808,"activeCount":97},[1809],{"nctId":1810,"briefTitle":1811,"status":144,"phases":1812,"primaryCompletion":1813,"completion":1813,"start":1814,"enrollment":1815,"conditions":1816,"interventions":1819},"NCT01690585","Efficacy of Parenteral Iron Supplementation After Gastrointestinal Bleeding in Subjects Over 65",[88],"2017-07","2013-01",62,[1817,1818],"Gastrointestinal Hemorrhage","Anemia",[1799,1820],"Sodium chlorure 0,9 %",{"trials":1822,"activeCount":97},[],{"trials":1824,"activeCount":97},[],{"intervention":1820,"totalTrials":118,"cells":1826},{"EARLY_PHASE1":1827,"PHASE1":1829,"PHASE2":1831,"PHASE3":1833,"PHASE4":1839,"NA":1841},{"trials":1828,"activeCount":97},[],{"trials":1830,"activeCount":97},[],{"trials":1832,"activeCount":97},[],{"trials":1834,"activeCount":97},[1835],{"nctId":1810,"briefTitle":1811,"status":144,"phases":1836,"primaryCompletion":1813,"completion":1813,"start":1814,"enrollment":1815,"conditions":1837,"interventions":1838},[88],[1817,1818],[1799,1820],{"trials":1840,"activeCount":97},[],{"trials":1842,"activeCount":97},[],{"intervention":1844,"totalTrials":118,"cells":1845},"Eculizumab administration",{"EARLY_PHASE1":1846,"PHASE1":1848,"PHASE2":1850,"PHASE3":1852,"PHASE4":1865,"NA":1867},{"trials":1847,"activeCount":97},[],{"trials":1849,"activeCount":97},[],{"trials":1851,"activeCount":97},[],{"trials":1853,"activeCount":97},[1854],{"nctId":1855,"briefTitle":1856,"status":1857,"phases":1858,"primaryCompletion":1859,"completion":1859,"start":1860,"enrollment":1861,"conditions":1862,"interventions":1864},"NCT05702996","Multicenter, Uncontrolled Pilot Study Evaluating the Efficacy of Eculizumab in the Treatment of Gemcitabine-induced Thrombotic Microangiopathies","UNKNOWN",[88],"2025-09","2023-03",10,[1863],"Thrombotic Microangiopathies",[1844],{"trials":1866,"activeCount":97},[],{"trials":1868,"activeCount":97},[],{"intervention":1870,"totalTrials":118,"cells":1871},"Infusion of Ropivacaine during 48 hours",{"EARLY_PHASE1":1872,"PHASE1":1874,"PHASE2":1876,"PHASE3":1878,"PHASE4":1892,"NA":1894},{"trials":1873,"activeCount":97},[],{"trials":1875,"activeCount":97},[],{"trials":1877,"activeCount":97},[],{"trials":1879,"activeCount":97},[1880],{"nctId":1881,"briefTitle":1882,"status":995,"phases":1883,"primaryCompletion":1884,"completion":1884,"start":1885,"enrollment":1886,"conditions":1887,"interventions":1889},"NCT02353702","Efficacy of Local Anesthesic on Diaphragmatic Function After Upper Abdominal Surgery",[88],"2017-06","2014-07",31,[1888],"Hepatectomy",[1870,1890,1891],"Infusion of placebo during 48 hours","NaCl",{"trials":1893,"activeCount":97},[],{"trials":1895,"activeCount":97},[],{"intervention":1890,"totalTrials":118,"cells":1897},{"EARLY_PHASE1":1898,"PHASE1":1900,"PHASE2":1902,"PHASE3":1904,"PHASE4":1910,"NA":1912},{"trials":1899,"activeCount":97},[],{"trials":1901,"activeCount":97},[],{"trials":1903,"activeCount":97},[],{"trials":1905,"activeCount":97},[1906],{"nctId":1881,"briefTitle":1882,"status":995,"phases":1907,"primaryCompletion":1884,"completion":1884,"start":1885,"enrollment":1886,"conditions":1908,"interventions":1909},[88],[1888],[1870,1890,1891],{"trials":1911,"activeCount":97},[],{"trials":1913,"activeCount":97},[],{"intervention":1891,"totalTrials":118,"cells":1915},{"EARLY_PHASE1":1916,"PHASE1":1918,"PHASE2":1920,"PHASE3":1922,"PHASE4":1928,"NA":1930},{"trials":1917,"activeCount":97},[],{"trials":1919,"activeCount":97},[],{"trials":1921,"activeCount":97},[],{"trials":1923,"activeCount":97},[1924],{"nctId":1881,"briefTitle":1882,"status":995,"phases":1925,"primaryCompletion":1884,"completion":1884,"start":1885,"enrollment":1886,"conditions":1926,"interventions":1927},[88],[1888],[1870,1890,1891],{"trials":1929,"activeCount":97},[],{"trials":1931,"activeCount":97},[],{"intervention":1933,"totalTrials":118,"cells":1934},"Sirolimus",{"EARLY_PHASE1":1935,"PHASE1":1937,"PHASE2":1939,"PHASE3":1941,"PHASE4":1953,"NA":1955},{"trials":1936,"activeCount":97},[],{"trials":1938,"activeCount":97},[],{"trials":1940,"activeCount":97},[],{"trials":1942,"activeCount":97},[1943],{"nctId":1944,"briefTitle":1945,"status":995,"phases":1946,"primaryCompletion":167,"completion":1947,"start":1948,"enrollment":1949,"conditions":1950,"interventions":1952},"NCT00811915","Study to Compare the Safety and Efficacy of Sirolimus (Rapamune) to Tacrolimus (Advagraf) Associated to Mycophenolate Mofetil (CellCept) Between 12 and 36 Months After Kidney Transplantation",[88],"2014-06","2009-01",65,[1951],"Kidney Transplantation",[1933],{"trials":1954,"activeCount":97},[],{"trials":1956,"activeCount":97},[],{"intervention":1958,"totalTrials":118,"cells":1959},"Steroid + cyclophosphamide",{"EARLY_PHASE1":1960,"PHASE1":1962,"PHASE2":1964,"PHASE3":1966,"PHASE4":1979,"NA":1981},{"trials":1961,"activeCount":97},[],{"trials":1963,"activeCount":97},[],{"trials":1965,"activeCount":97},[],{"trials":1967,"activeCount":97},[1968],{"nctId":1969,"briefTitle":1970,"status":144,"phases":1971,"primaryCompletion":1972,"completion":1972,"start":1973,"enrollment":1974,"conditions":1975,"interventions":1977},"NCT01808911","Outcome of Acquired Haemophilia With Steroid Combined With Cyclophosphamide Versus Steroid Combined With Rituximab (CREHA Study)",[88],"2021-01-14","2012-05",110,[1976],"Acquired Haemophilia",[1958,1978],"Steroid + rituximab",{"trials":1980,"activeCount":97},[],{"trials":1982,"activeCount":97},[],{"intervention":1978,"totalTrials":118,"cells":1984},{"EARLY_PHASE1":1985,"PHASE1":1987,"PHASE2":1989,"PHASE3":1991,"PHASE4":1997,"NA":1999},{"trials":1986,"activeCount":97},[],{"trials":1988,"activeCount":97},[],{"trials":1990,"activeCount":97},[],{"trials":1992,"activeCount":97},[1993],{"nctId":1969,"briefTitle":1970,"status":144,"phases":1994,"primaryCompletion":1972,"completion":1972,"start":1973,"enrollment":1974,"conditions":1995,"interventions":1996},[88],[1976],[1958,1978],{"trials":1998,"activeCount":97},[],{"trials":2000,"activeCount":97},[],{"intervention":174,"totalTrials":118,"cells":2002},{"EARLY_PHASE1":2003,"PHASE1":2005,"PHASE2":2007,"PHASE3":2009,"PHASE4":2015,"NA":2017},{"trials":2004,"activeCount":97},[],{"trials":2006,"activeCount":97},[],{"trials":2008,"activeCount":97},[],{"trials":2010,"activeCount":97},[2011],{"nctId":164,"briefTitle":165,"status":144,"phases":2012,"primaryCompletion":167,"completion":168,"start":169,"enrollment":170,"conditions":2013,"interventions":2014},[88],[172],[174,131],{"trials":2016,"activeCount":97},[],{"trials":2018,"activeCount":97},[],{"intervention":1655,"totalTrials":118,"cells":2020},{"EARLY_PHASE1":2021,"PHASE1":2023,"PHASE2":2025,"PHASE3":2027,"PHASE4":2033,"NA":2035},{"trials":2022,"activeCount":97},[],{"trials":2024,"activeCount":97},[],{"trials":2026,"activeCount":97},[],{"trials":2028,"activeCount":97},[2029],{"nctId":1647,"briefTitle":1648,"status":144,"phases":2030,"primaryCompletion":1650,"completion":1650,"start":1651,"enrollment":1652,"conditions":2031,"interventions":2032},[88],[18],[1655,1625],{"trials":2034,"activeCount":97},[],{"trials":2036,"activeCount":97},[],{"intervention":2038,"totalTrials":118,"cells":2039},"GEMCITABINE CISPLATINE",{"EARLY_PHASE1":2040,"PHASE1":2042,"PHASE2":2044,"PHASE3":2046,"PHASE4":2058,"NA":2060},{"trials":2041,"activeCount":97},[],{"trials":2043,"activeCount":97},[],{"trials":2045,"activeCount":97},[],{"trials":2047,"activeCount":97},[2048],{"nctId":2049,"briefTitle":2050,"status":144,"phases":2051,"primaryCompletion":2052,"completion":2052,"start":1555,"enrollment":2053,"conditions":2054,"interventions":2056},"NCT01812369","Perioperative Chemotherapy for Patients With Locally Advanced Bladder Cancer",[88],"2023-09-25",500,[2055],"Bladder Cancer",[2038,2057],"METHOTRXATE VINBLASTINE DOXORUBICINE CISPLATINE G-CSF",{"trials":2059,"activeCount":97},[],{"trials":2061,"activeCount":97},[],{"intervention":2057,"totalTrials":118,"cells":2063},{"EARLY_PHASE1":2064,"PHASE1":2066,"PHASE2":2068,"PHASE3":2070,"PHASE4":2076,"NA":2078},{"trials":2065,"activeCount":97},[],{"trials":2067,"activeCount":97},[],{"trials":2069,"activeCount":97},[],{"trials":2071,"activeCount":97},[2072],{"nctId":2049,"briefTitle":2050,"status":144,"phases":2073,"primaryCompletion":2052,"completion":2052,"start":1555,"enrollment":2053,"conditions":2074,"interventions":2075},[88],[2055],[2038,2057],{"trials":2077,"activeCount":97},[],{"trials":2079,"activeCount":97},[],{"intervention":2081,"totalTrials":118,"cells":2082},"Methotrexate",{"EARLY_PHASE1":2083,"PHASE1":2085,"PHASE2":2087,"PHASE3":2089,"PHASE4":2100,"NA":2102},{"trials":2084,"activeCount":97},[],{"trials":2086,"activeCount":97},[],{"trials":2088,"activeCount":97},[],{"trials":2090,"activeCount":97},[2091],{"nctId":2092,"briefTitle":2093,"status":144,"phases":2094,"primaryCompletion":2095,"completion":2095,"start":2096,"enrollment":170,"conditions":2097,"interventions":2099},"NCT02037191","The Efficiency Of The Methotrexate At Patients Affected By Grave Pelade",[88],"2017-12","2014-02",[2098],"ALOPECIA AREATA",[2081],{"trials":2101,"activeCount":97},[],{"trials":2103,"activeCount":97},[],{"intervention":2105,"totalTrials":118,"cells":2106},"Protopic",{"EARLY_PHASE1":2107,"PHASE1":2109,"PHASE2":2111,"PHASE3":2113,"PHASE4":2125,"NA":2127},{"trials":2108,"activeCount":97},[],{"trials":2110,"activeCount":97},[],{"trials":2112,"activeCount":97},[],{"trials":2114,"activeCount":97},[2115],{"nctId":2116,"briefTitle":2117,"status":144,"phases":2118,"primaryCompletion":2119,"completion":2119,"start":2120,"enrollment":827,"conditions":2121,"interventions":2123},"NCT02004860","Tacrolimus Ointment Interest (PROTOPIC ®) in the Maintenance Treatment of Severe Seborrheic Dermatitis",[88],"2017-10","2014-01",[2122],"Severe Seborrheic Dermatitis",[2105,2124],"Mycoster",{"trials":2126,"activeCount":97},[],{"trials":2128,"activeCount":97},[],{"intervention":2124,"totalTrials":118,"cells":2130},{"EARLY_PHASE1":2131,"PHASE1":2133,"PHASE2":2135,"PHASE3":2137,"PHASE4":2143,"NA":2145},{"trials":2132,"activeCount":97},[],{"trials":2134,"activeCount":97},[],{"trials":2136,"activeCount":97},[],{"trials":2138,"activeCount":97},[2139],{"nctId":2116,"briefTitle":2117,"status":144,"phases":2140,"primaryCompletion":2119,"completion":2119,"start":2120,"enrollment":827,"conditions":2141,"interventions":2142},[88],[2122],[2105,2124],{"trials":2144,"activeCount":97},[],{"trials":2146,"activeCount":97},[],{"intervention":2148,"totalTrials":118,"cells":2149},"Tegeline®",{"EARLY_PHASE1":2150,"PHASE1":2152,"PHASE2":2154,"PHASE3":2156,"PHASE4":2166,"NA":2168},{"trials":2151,"activeCount":97},[],{"trials":2153,"activeCount":97},[],{"trials":2155,"activeCount":97},[],{"trials":2157,"activeCount":97},[2158],{"nctId":2159,"briefTitle":2160,"status":995,"phases":2161,"primaryCompletion":1435,"completion":1435,"start":2162,"enrollment":25,"conditions":2163,"interventions":2165},"NCT00505648","Treatment of Hypersensitivity Syndrome (DRESS) With Tegeline® (Human Immunoglobulin)",[88],"2008-01",[2164],"Drug Hypersensitivity",[2148],{"trials":2167,"activeCount":97},[],{"trials":2169,"activeCount":97},[],{"intervention":1002,"totalTrials":118,"cells":2171},{"EARLY_PHASE1":2172,"PHASE1":2174,"PHASE2":2176,"PHASE3":2178,"PHASE4":2184,"NA":2186},{"trials":2173,"activeCount":97},[],{"trials":2175,"activeCount":97},[],{"trials":2177,"activeCount":97},[],{"trials":2179,"activeCount":97},[2180],{"nctId":993,"briefTitle":994,"status":995,"phases":2181,"primaryCompletion":997,"completion":997,"start":998,"enrollment":827,"conditions":2182,"interventions":2183},[88],[1000],[1002,74,1003,1004],{"trials":2185,"activeCount":97},[],{"trials":2187,"activeCount":97},[],{"intervention":1003,"totalTrials":118,"cells":2189},{"EARLY_PHASE1":2190,"PHASE1":2192,"PHASE2":2194,"PHASE3":2196,"PHASE4":2202,"NA":2204},{"trials":2191,"activeCount":97},[],{"trials":2193,"activeCount":97},[],{"trials":2195,"activeCount":97},[],{"trials":2197,"activeCount":97},[2198],{"nctId":993,"briefTitle":994,"status":995,"phases":2199,"primaryCompletion":997,"completion":997,"start":998,"enrollment":827,"conditions":2200,"interventions":2201},[88],[1000],[1002,74,1003,1004],{"trials":2203,"activeCount":97},[],{"trials":2205,"activeCount":97},[],{"intervention":1004,"totalTrials":118,"cells":2207},{"EARLY_PHASE1":2208,"PHASE1":2210,"PHASE2":2212,"PHASE3":2214,"PHASE4":2220,"NA":2222},{"trials":2209,"activeCount":97},[],{"trials":2211,"activeCount":97},[],{"trials":2213,"activeCount":97},[],{"trials":2215,"activeCount":97},[2216],{"nctId":993,"briefTitle":994,"status":995,"phases":2217,"primaryCompletion":997,"completion":997,"start":998,"enrollment":827,"conditions":2218,"interventions":2219},[88],[1000],[1002,74,1003,1004],{"trials":2221,"activeCount":97},[],{"trials":2223,"activeCount":97},[],{"intervention":2225,"totalTrials":118,"cells":2226},"Metronidazole",{"EARLY_PHASE1":2227,"PHASE1":2229,"PHASE2":2231,"PHASE3":2233,"PHASE4":2246,"NA":2248},{"trials":2228,"activeCount":97},[],{"trials":2230,"activeCount":97},[],{"trials":2232,"activeCount":97},[],{"trials":2234,"activeCount":97},[2235],{"nctId":2236,"briefTitle":2237,"status":144,"phases":2238,"primaryCompletion":2239,"completion":2239,"start":2240,"enrollment":2241,"conditions":2242,"interventions":2244},"NCT01275560","Does the Negativation of the Glucose Hydrogen Breath Test Come Along With a Reduction of the Symptoms of Gaz Incontinence ?",[88],"2015-06","2011-01",16,[2243],"Anal Incontinence",[2225,2245],"CArbosylane",{"trials":2247,"activeCount":97},[],{"trials":2249,"activeCount":97},[],{"intervention":2245,"totalTrials":118,"cells":2251},{"EARLY_PHASE1":2252,"PHASE1":2254,"PHASE2":2256,"PHASE3":2258,"PHASE4":2264,"NA":2266},{"trials":2253,"activeCount":97},[],{"trials":2255,"activeCount":97},[],{"trials":2257,"activeCount":97},[],{"trials":2259,"activeCount":97},[2260],{"nctId":2236,"briefTitle":2237,"status":144,"phases":2261,"primaryCompletion":2239,"completion":2239,"start":2240,"enrollment":2241,"conditions":2262,"interventions":2263},[88],[2243],[2225,2245],{"trials":2265,"activeCount":97},[],{"trials":2267,"activeCount":97},[],{"intervention":2269,"totalTrials":118,"cells":2270},"inhaled titration of morphine chlorhydrate",{"EARLY_PHASE1":2271,"PHASE1":2273,"PHASE2":2275,"PHASE3":2277,"PHASE4":2292,"NA":2294},{"trials":2272,"activeCount":97},[],{"trials":2274,"activeCount":97},[],{"trials":2276,"activeCount":97},[],{"trials":2278,"activeCount":97},[2279],{"nctId":2280,"briefTitle":2281,"status":144,"phases":2282,"primaryCompletion":2283,"completion":2283,"start":2284,"enrollment":2285,"conditions":2286,"interventions":2289},"NCT03257319","Inhaled vs IV Opioid Dosing for the Initial Treatment of Severe Acute Pain in the Emergency Department",[88],"2022-07-29","2017-09-19",226,[2287,952,2288],"Pain, Acute","Morphine",[2269,2290,2291],"IV placebo","IV titration of morphine chlorhydrate",{"trials":2293,"activeCount":97},[],{"trials":2295,"activeCount":97},[],{"intervention":2290,"totalTrials":118,"cells":2297},{"EARLY_PHASE1":2298,"PHASE1":2300,"PHASE2":2302,"PHASE3":2304,"PHASE4":2310,"NA":2312},{"trials":2299,"activeCount":97},[],{"trials":2301,"activeCount":97},[],{"trials":2303,"activeCount":97},[],{"trials":2305,"activeCount":97},[2306],{"nctId":2280,"briefTitle":2281,"status":144,"phases":2307,"primaryCompletion":2283,"completion":2283,"start":2284,"enrollment":2285,"conditions":2308,"interventions":2309},[88],[2287,952,2288],[2269,2290,2291],{"trials":2311,"activeCount":97},[],{"trials":2313,"activeCount":97},[],{"intervention":2291,"totalTrials":118,"cells":2315},{"EARLY_PHASE1":2316,"PHASE1":2318,"PHASE2":2320,"PHASE3":2322,"PHASE4":2328,"NA":2330},{"trials":2317,"activeCount":97},[],{"trials":2319,"activeCount":97},[],{"trials":2321,"activeCount":97},[],{"trials":2323,"activeCount":97},[2324],{"nctId":2280,"briefTitle":2281,"status":144,"phases":2325,"primaryCompletion":2283,"completion":2283,"start":2284,"enrollment":2285,"conditions":2326,"interventions":2327},[88],[2287,952,2288],[2269,2290,2291],{"trials":2329,"activeCount":97},[],{"trials":2331,"activeCount":97},[],{"intervention":2333,"totalTrials":118,"cells":2334},"cyclosporine A",{"EARLY_PHASE1":2335,"PHASE1":2337,"PHASE2":2339,"PHASE3":2341,"PHASE4":2353,"NA":2355},{"trials":2336,"activeCount":97},[],{"trials":2338,"activeCount":97},[],{"trials":2340,"activeCount":97},[],{"trials":2342,"activeCount":97},[2343],{"nctId":2344,"briefTitle":2345,"status":144,"phases":2346,"primaryCompletion":1204,"completion":1204,"start":2347,"enrollment":2348,"conditions":2349,"interventions":2352},"NCT00213590","Renal Function Evaluation After Reduction of Cyclosporine A Dose in Renal Transplant Patients",[88],"2000-04",208,[1951,2350,2351],"Primary Prevention","Kidney Failure",[2333],{"trials":2354,"activeCount":97},[],{"trials":2356,"activeCount":97},[],{"intervention":2358,"totalTrials":118,"cells":2359},"Terlipressin administration",{"EARLY_PHASE1":2360,"PHASE1":2362,"PHASE2":2364,"PHASE3":2366,"PHASE4":2377,"NA":2379},{"trials":2361,"activeCount":97},[],{"trials":2363,"activeCount":97},[],{"trials":2365,"activeCount":97},[],{"trials":2367,"activeCount":97},[2368],{"nctId":2369,"briefTitle":2370,"status":144,"phases":2371,"primaryCompletion":2372,"completion":2372,"start":2373,"enrollment":497,"conditions":2374,"interventions":2376},"NCT02970175","Interest of in Situ Terlipressin Administration Before the Realisation of Bronchial Biopsy",[88],"2024-04-25","2017-06-30",[2375],"Bronchial Endoscopy",[2358],{"trials":2378,"activeCount":97},[],{"trials":2380,"activeCount":97},[],{"intervention":2382,"totalTrials":118,"cells":2383},"Botulinum toxin A or physiologic serum",{"EARLY_PHASE1":2384,"PHASE1":2386,"PHASE2":2388,"PHASE3":2390,"PHASE4":2400,"NA":2402},{"trials":2385,"activeCount":97},[],{"trials":2387,"activeCount":97},[],{"trials":2389,"activeCount":97},[],{"trials":2391,"activeCount":97},[2392],{"nctId":2393,"briefTitle":2394,"status":144,"phases":2395,"primaryCompletion":2396,"completion":2396,"start":2397,"enrollment":1619,"conditions":2398,"interventions":2399},"NCT02414425","Effect and Tolerance of Botulinum A Toxin Rectal Injections on Fecal Incontinence",[88],"2022-03-30","2015-11-25",[21],[2382],{"trials":2401,"activeCount":97},[],{"trials":2403,"activeCount":97},[],{"intervention":2405,"totalTrials":118,"cells":2406},"standard chemotherapy for colorectal cancer",{"EARLY_PHASE1":2407,"PHASE1":2409,"PHASE2":2411,"PHASE3":2413,"PHASE4":2425,"NA":2427},{"trials":2408,"activeCount":97},[],{"trials":2410,"activeCount":97},[],{"trials":2412,"activeCount":97},[],{"trials":2414,"activeCount":97},[2415],{"nctId":2416,"briefTitle":2417,"status":144,"phases":2418,"primaryCompletion":2419,"completion":2419,"start":2420,"enrollment":2421,"conditions":2422,"interventions":2424},"NCT02956876","Equivalence of Monitoring by a Nurse Practitioner for Patients With Digestive Cancer",[88],"2022-11-19","2016-12-05",207,[2423],"ColoRectal Cancer",[2405],{"trials":2426,"activeCount":97},[],{"trials":2428,"activeCount":97},[],{"intervention":2430,"totalTrials":118,"cells":2431},"Triptoreline 11.25 i.v.; Estradiol 0.5% percutaneous gel;",{"EARLY_PHASE1":2432,"PHASE1":2434,"PHASE2":2436,"PHASE3":2438,"PHASE4":2452,"NA":2454},{"trials":2433,"activeCount":97},[],{"trials":2435,"activeCount":97},[],{"trials":2437,"activeCount":97},[],{"trials":2439,"activeCount":97},[2440],{"nctId":2441,"briefTitle":2442,"status":144,"phases":2443,"primaryCompletion":2444,"completion":2444,"start":2445,"enrollment":2446,"conditions":2447,"interventions":2449},"NCT01973816","MEdical Versus SUrgical Treatments of Rectal Endometriosis",[88],"2022-10-11","2014-09-09",78,[2448],"Endometriosis",[2430,2450,2451],"Cyproterone acetate 50 mg; estradiol 0.5% percutaneous","Estradiol 0.5% percutaneous gel; Cyproterone acetate 50 mg",{"trials":2453,"activeCount":97},[],{"trials":2455,"activeCount":97},[],{"intervention":2450,"totalTrials":118,"cells":2457},{"EARLY_PHASE1":2458,"PHASE1":2460,"PHASE2":2462,"PHASE3":2464,"PHASE4":2470,"NA":2472},{"trials":2459,"activeCount":97},[],{"trials":2461,"activeCount":97},[],{"trials":2463,"activeCount":97},[],{"trials":2465,"activeCount":97},[2466],{"nctId":2441,"briefTitle":2442,"status":144,"phases":2467,"primaryCompletion":2444,"completion":2444,"start":2445,"enrollment":2446,"conditions":2468,"interventions":2469},[88],[2448],[2430,2450,2451],{"trials":2471,"activeCount":97},[],{"trials":2473,"activeCount":97},[],{"intervention":2451,"totalTrials":118,"cells":2475},{"EARLY_PHASE1":2476,"PHASE1":2478,"PHASE2":2480,"PHASE3":2482,"PHASE4":2488,"NA":2490},{"trials":2477,"activeCount":97},[],{"trials":2479,"activeCount":97},[],{"trials":2481,"activeCount":97},[],{"trials":2483,"activeCount":97},[2484],{"nctId":2441,"briefTitle":2442,"status":144,"phases":2485,"primaryCompletion":2444,"completion":2444,"start":2445,"enrollment":2446,"conditions":2486,"interventions":2487},[88],[2448],[2430,2450,2451],{"trials":2489,"activeCount":97},[],{"trials":2491,"activeCount":97},[],{"intervention":2493,"totalTrials":118,"cells":2494},"Enoxaparin",{"EARLY_PHASE1":2495,"PHASE1":2497,"PHASE2":2499,"PHASE3":2501,"PHASE4":2513,"NA":2515},{"trials":2496,"activeCount":97},[],{"trials":2498,"activeCount":97},[],{"trials":2500,"activeCount":97},[],{"trials":2502,"activeCount":97},[2503],{"nctId":2504,"briefTitle":2505,"status":144,"phases":2506,"primaryCompletion":2507,"completion":2507,"start":2508,"enrollment":2509,"conditions":2510,"interventions":2512},"NCT01707732","Adjusted Value of Thromboprophylaxis in Hospitalized Obese Patients: A Comparative Study of Two Regimens of Enoxaparin",[88],"2015-04","2012-11",92,[2511],"Thromboprophylaxis in Hospitalized Obese Patients",[2493],{"trials":2514,"activeCount":97},[],{"trials":2516,"activeCount":97},[],{"intervention":2518,"totalTrials":118,"cells":2519},"Nifedipine",{"EARLY_PHASE1":2520,"PHASE1":2522,"PHASE2":2524,"PHASE3":2534,"PHASE4":2536,"NA":2538},{"trials":2521,"activeCount":97},[],{"trials":2523,"activeCount":97},[],{"trials":2525,"activeCount":97},[2526],{"nctId":2527,"briefTitle":2528,"status":144,"phases":2529,"primaryCompletion":158,"completion":2530,"start":2162,"enrollment":8,"conditions":2531,"interventions":2533},"NCT00620724","Tocolytic Therapy in Conservative Management of Symptomatic Placenta Previa",[87],"2012-09",[2532],"Placenta Previa",[2518],{"trials":2535,"activeCount":97},[],{"trials":2537,"activeCount":97},[],{"trials":2539,"activeCount":97},[],{"intervention":2541,"totalTrials":118,"cells":2542},"type A botulinum toxin",{"EARLY_PHASE1":2543,"PHASE1":2545,"PHASE2":2547,"PHASE3":2558,"PHASE4":2560,"NA":2562},{"trials":2544,"activeCount":97},[],{"trials":2546,"activeCount":97},[],{"trials":2548,"activeCount":97},[2549],{"nctId":2550,"briefTitle":2551,"status":995,"phases":2552,"primaryCompletion":2553,"completion":997,"start":2554,"enrollment":148,"conditions":2555,"interventions":2557},"NCT00213577","NEUROTOX: Two Dosages of Type A Botulinic Toxin in Neurogenic Overactive Bladder",[87],"2007-09","2003-12",[2556],"Overactive Bladder",[2541],{"trials":2559,"activeCount":97},[],{"trials":2561,"activeCount":97},[],{"trials":2563,"activeCount":97},[],{"intervention":1643,"totalTrials":118,"cells":2565},{"EARLY_PHASE1":2566,"PHASE1":2568,"PHASE2":2570,"PHASE3":2576,"PHASE4":2578,"NA":2580},{"trials":2567,"activeCount":97},[],{"trials":2569,"activeCount":97},[],{"trials":2571,"activeCount":97},[2572],{"nctId":1634,"briefTitle":1635,"status":144,"phases":2573,"primaryCompletion":1637,"completion":1637,"start":1638,"enrollment":1639,"conditions":2574,"interventions":2575},[86,87],[1641,18],[1625,1643],{"trials":2577,"activeCount":97},[],{"trials":2579,"activeCount":97},[],{"trials":2581,"activeCount":97},[],{"intervention":2288,"totalTrials":118,"cells":2583},{"EARLY_PHASE1":2584,"PHASE1":2586,"PHASE2":2588,"PHASE3":2601,"PHASE4":2603,"NA":2605},{"trials":2585,"activeCount":97},[],{"trials":2587,"activeCount":97},[],{"trials":2589,"activeCount":97},[2590],{"nctId":2591,"briefTitle":2592,"status":144,"phases":2593,"primaryCompletion":2594,"completion":2594,"start":2595,"enrollment":2596,"conditions":2597,"interventions":2599},"NCT01975753","First Evaluation of Morphine Hydrochloride by Nebulisation in Healthy Volunteers",[86,87],"2018-05-02","2014-05-13",35,[2598],"Acute Pain",[2288,2600],"Fentanyl",{"trials":2602,"activeCount":97},[],{"trials":2604,"activeCount":97},[],{"trials":2606,"activeCount":97},[],{"intervention":2600,"totalTrials":118,"cells":2608},{"EARLY_PHASE1":2609,"PHASE1":2611,"PHASE2":2613,"PHASE3":2619,"PHASE4":2621,"NA":2623},{"trials":2610,"activeCount":97},[],{"trials":2612,"activeCount":97},[],{"trials":2614,"activeCount":97},[2615],{"nctId":2591,"briefTitle":2592,"status":144,"phases":2616,"primaryCompletion":2594,"completion":2594,"start":2595,"enrollment":2596,"conditions":2617,"interventions":2618},[86,87],[2598],[2288,2600],{"trials":2620,"activeCount":97},[],{"trials":2622,"activeCount":97},[],{"trials":2624,"activeCount":97},[],{"intervention":2626,"totalTrials":118,"cells":2627},"FOLFOX neoadjuvant chemotherapy",{"EARLY_PHASE1":2628,"PHASE1":2630,"PHASE2":2632,"PHASE3":2647,"PHASE4":2649,"NA":2651},{"trials":2629,"activeCount":97},[],{"trials":2631,"activeCount":97},[],{"trials":2633,"activeCount":97},[2634],{"nctId":2635,"briefTitle":2636,"status":144,"phases":2637,"primaryCompletion":2638,"completion":2638,"start":2639,"enrollment":2640,"conditions":2641,"interventions":2643},"NCT02959879","Neo-adjuvant FOLF(IRIN)OX for Resectable Pancreatic Adenocarcinoma",[87],"2023-08-08","2017-03-01",153,[2642],"Resectable Pancreatic Duct Adenocarcinoma",[2626,2644,2645,2646],"FOLFIRINOX neoadjuvant chemotherapy","Standard adjuvant chemotherapy","adjuvant chemotherapy",{"trials":2648,"activeCount":97},[],{"trials":2650,"activeCount":97},[],{"trials":2652,"activeCount":97},[],{"intervention":2644,"totalTrials":118,"cells":2654},{"EARLY_PHASE1":2655,"PHASE1":2657,"PHASE2":2659,"PHASE3":2665,"PHASE4":2667,"NA":2669},{"trials":2656,"activeCount":97},[],{"trials":2658,"activeCount":97},[],{"trials":2660,"activeCount":97},[2661],{"nctId":2635,"briefTitle":2636,"status":144,"phases":2662,"primaryCompletion":2638,"completion":2638,"start":2639,"enrollment":2640,"conditions":2663,"interventions":2664},[87],[2642],[2626,2644,2645,2646],{"trials":2666,"activeCount":97},[],{"trials":2668,"activeCount":97},[],{"trials":2670,"activeCount":97},[],{"intervention":2645,"totalTrials":118,"cells":2672},{"EARLY_PHASE1":2673,"PHASE1":2675,"PHASE2":2677,"PHASE3":2683,"PHASE4":2685,"NA":2687},{"trials":2674,"activeCount":97},[],{"trials":2676,"activeCount":97},[],{"trials":2678,"activeCount":97},[2679],{"nctId":2635,"briefTitle":2636,"status":144,"phases":2680,"primaryCompletion":2638,"completion":2638,"start":2639,"enrollment":2640,"conditions":2681,"interventions":2682},[87],[2642],[2626,2644,2645,2646],{"trials":2684,"activeCount":97},[],{"trials":2686,"activeCount":97},[],{"trials":2688,"activeCount":97},[],{"intervention":2646,"totalTrials":118,"cells":2690},{"EARLY_PHASE1":2691,"PHASE1":2693,"PHASE2":2695,"PHASE3":2701,"PHASE4":2703,"NA":2705},{"trials":2692,"activeCount":97},[],{"trials":2694,"activeCount":97},[],{"trials":2696,"activeCount":97},[2697],{"nctId":2635,"briefTitle":2636,"status":144,"phases":2698,"primaryCompletion":2638,"completion":2638,"start":2639,"enrollment":2640,"conditions":2699,"interventions":2700},[87],[2642],[2626,2644,2645,2646],{"trials":2702,"activeCount":97},[],{"trials":2704,"activeCount":97},[],{"trials":2706,"activeCount":97},[],{"intervention":2708,"totalTrials":118,"cells":2709},"Dapagliflozin 10Mg Tab",{"EARLY_PHASE1":2710,"PHASE1":2712,"PHASE2":2714,"PHASE3":2726,"PHASE4":2728,"NA":2730},{"trials":2711,"activeCount":97},[],{"trials":2713,"activeCount":97},[],{"trials":2715,"activeCount":97},[2716],{"nctId":2717,"briefTitle":2718,"status":144,"phases":2719,"primaryCompletion":2720,"completion":2720,"start":2721,"enrollment":2722,"conditions":2723,"interventions":2725},"NCT04930549","Vascular Impact of Dapagliflozin in CKD Patients (DAPAVASC)",[87],"2024-09-23","2022-10-18",32,[2724],"Renal Insufficiency, Chronic",[2708],{"trials":2727,"activeCount":97},[],{"trials":2729,"activeCount":97},[],{"trials":2731,"activeCount":97},[],{"intervention":2733,"totalTrials":118,"cells":2734},"Administration of Aprepitant",{"EARLY_PHASE1":2735,"PHASE1":2737,"PHASE2":2739,"PHASE3":2753,"PHASE4":2755,"NA":2757},{"trials":2736,"activeCount":97},[],{"trials":2738,"activeCount":97},[],{"trials":2740,"activeCount":97},[2741],{"nctId":2742,"briefTitle":2743,"status":144,"phases":2744,"primaryCompletion":2745,"completion":2745,"start":2746,"enrollment":32,"conditions":2747,"interventions":2750},"NCT02811055","Pilot Study of Aprepitant Effect on Aldosterone Secretion in Diabetic Patient (Diabetes Mellitus) With Hypertension Associated With Low Renin",[87],"2020-12-05","2017-07-13",[2748,2749],"Type 2 Diabetes","Hypertension",[2751,2733,2752],"Blood sampling","Administration of placebo",{"trials":2754,"activeCount":97},[],{"trials":2756,"activeCount":97},[],{"trials":2758,"activeCount":97},[],{"intervention":2752,"totalTrials":118,"cells":2760},{"EARLY_PHASE1":2761,"PHASE1":2763,"PHASE2":2765,"PHASE3":2771,"PHASE4":2773,"NA":2775},{"trials":2762,"activeCount":97},[],{"trials":2764,"activeCount":97},[],{"trials":2766,"activeCount":97},[2767],{"nctId":2742,"briefTitle":2743,"status":144,"phases":2768,"primaryCompletion":2745,"completion":2745,"start":2746,"enrollment":32,"conditions":2769,"interventions":2770},[87],[2748,2749],[2751,2733,2752],{"trials":2772,"activeCount":97},[],{"trials":2774,"activeCount":97},[],{"trials":2776,"activeCount":97},[],{"intervention":2778,"totalTrials":118,"cells":2779},"irinotecan",{"EARLY_PHASE1":2780,"PHASE1":2782,"PHASE2":2784,"PHASE3":2796,"PHASE4":2798,"NA":2800},{"trials":2781,"activeCount":97},[],{"trials":2783,"activeCount":97},[],{"trials":2785,"activeCount":97},[2786],{"nctId":2787,"briefTitle":2788,"status":144,"phases":2789,"primaryCompletion":2790,"completion":2790,"start":2791,"enrollment":2792,"conditions":2793,"interventions":2795},"NCT00213486","Weekly Cisplatin\u002FIrinotecan and Radiotherapy in Patients With Locally Advanced Esophageal Cancer: Phase II Trial",[87],"2006-06-23","2003-01-15",43,[2794],"Esophageal Neoplasms",[2778],{"trials":2797,"activeCount":97},[],{"trials":2799,"activeCount":97},[],{"trials":2801,"activeCount":97},[],{"intervention":2803,"totalTrials":118,"cells":2804},"Hydroxychloroquine",{"EARLY_PHASE1":2805,"PHASE1":2807,"PHASE2":2809,"PHASE3":2821,"PHASE4":2823,"NA":2825},{"trials":2806,"activeCount":97},[],{"trials":2808,"activeCount":97},[],{"trials":2810,"activeCount":97},[2811],{"nctId":2812,"briefTitle":2813,"status":995,"phases":2814,"primaryCompletion":2815,"completion":2815,"start":2816,"enrollment":2817,"conditions":2818,"interventions":2820},"NCT02595346","Study of the Efficiency of Hydroxychloroquine on the Endothelial Dysfunction and Its Vascular Consequences During the Antiphospholipid Syndrome",[87],"2020-08-05","2016-05-17",25,[2819],"Antiphospholipid Syndrome (APS)",[2803],{"trials":2822,"activeCount":97},[],{"trials":2824,"activeCount":97},[],{"trials":2826,"activeCount":97},[],{"intervention":2828,"totalTrials":118,"cells":2829},"Caplacizumab",{"EARLY_PHASE1":2830,"PHASE1":2832,"PHASE2":2834,"PHASE3":2845,"PHASE4":2847,"NA":2849},{"trials":2831,"activeCount":97},[],{"trials":2833,"activeCount":97},[],{"trials":2835,"activeCount":97},[2836],{"nctId":2837,"briefTitle":2838,"status":995,"phases":2839,"primaryCompletion":2840,"completion":2840,"start":2841,"enrollment":1708,"conditions":2842,"interventions":2844},"NCT04720261","Efficacy of a Personalized Caplacizumab Regimen Based on ADAMTS13 Activity Monitoring in Adult aTTP",[87],"2023-05-16","2021-04-26",[2843],"Thrombotic Thrombocytopenic Purpura, Acquired",[2828],{"trials":2846,"activeCount":97},[],{"trials":2848,"activeCount":97},[],{"trials":2850,"activeCount":97},[],{"intervention":2852,"totalTrials":118,"cells":2853},"Glutamine",{"EARLY_PHASE1":2854,"PHASE1":2856,"PHASE2":2868,"PHASE3":2870,"PHASE4":2872,"NA":2874},{"trials":2855,"activeCount":97},[],{"trials":2857,"activeCount":97},[2858],{"nctId":2859,"briefTitle":2860,"status":144,"phases":2861,"completion":2862,"start":2863,"enrollment":195,"conditions":2864,"interventions":2865},"NCT00213551","Glutamine and Intestinal Protein Metabolism",[86],"2008-06","2004-04",[1438],[2852,2866,2867],"Glucose","glutamine-antioxidants containing solution",{"trials":2869,"activeCount":97},[],{"trials":2871,"activeCount":97},[],{"trials":2873,"activeCount":97},[],{"trials":2875,"activeCount":97},[],{"intervention":2866,"totalTrials":118,"cells":2877},{"EARLY_PHASE1":2878,"PHASE1":2880,"PHASE2":2886,"PHASE3":2888,"PHASE4":2890,"NA":2892},{"trials":2879,"activeCount":97},[],{"trials":2881,"activeCount":97},[2882],{"nctId":2859,"briefTitle":2860,"status":144,"phases":2883,"completion":2862,"start":2863,"enrollment":195,"conditions":2884,"interventions":2885},[86],[1438],[2852,2866,2867],{"trials":2887,"activeCount":97},[],{"trials":2889,"activeCount":97},[],{"trials":2891,"activeCount":97},[],{"trials":2893,"activeCount":97},[],{"intervention":2867,"totalTrials":118,"cells":2895},{"EARLY_PHASE1":2896,"PHASE1":2898,"PHASE2":2904,"PHASE3":2906,"PHASE4":2908,"NA":2910},{"trials":2897,"activeCount":97},[],{"trials":2899,"activeCount":97},[2900],{"nctId":2859,"briefTitle":2860,"status":144,"phases":2901,"completion":2862,"start":2863,"enrollment":195,"conditions":2902,"interventions":2903},[86],[1438],[2852,2866,2867],{"trials":2905,"activeCount":97},[],{"trials":2907,"activeCount":97},[],{"trials":2909,"activeCount":97},[],{"trials":2911,"activeCount":97},[],{"intervention":2751,"totalTrials":32,"cells":2913},{"EARLY_PHASE1":2914,"PHASE1":2916,"PHASE2":2918,"PHASE3":2924,"PHASE4":2926,"NA":2928},{"trials":2915,"activeCount":97},[],{"trials":2917,"activeCount":97},[],{"trials":2919,"activeCount":97},[2920],{"nctId":2742,"briefTitle":2743,"status":144,"phases":2921,"primaryCompletion":2745,"completion":2745,"start":2746,"enrollment":32,"conditions":2922,"interventions":2923},[87],[2748,2749],[2751,2733,2752],{"trials":2925,"activeCount":97},[],{"trials":2927,"activeCount":97},[],{"trials":2929,"activeCount":97},[2930,2939,2947,2958],{"nctId":2931,"briefTitle":2932,"status":144,"phases":2933,"primaryCompletion":2934,"completion":2934,"start":2935,"enrollment":2936,"conditions":2937,"interventions":2938},"NCT02557061","Prognostic Value of the Lymphocytic Infiltrate in Colon Cancers",[90],"2016-08","2009-04",56,[632],[2751],{"nctId":2940,"briefTitle":2941,"status":144,"phases":2942,"primaryCompletion":2943,"completion":2943,"start":2943,"enrollment":1861,"conditions":2944,"interventions":2946},"NCT04266587","ACTH Stability on Whole Blood",[90],"2021-11-18",[2945],"ACTH",[2751],{"nctId":2948,"briefTitle":2949,"status":144,"phases":2950,"primaryCompletion":2951,"completion":1531,"start":2952,"enrollment":195,"conditions":2953,"interventions":2956},"NCT02556320","Immunological and Viral Parameters in Patients Receiving Anti-epileptic Drugs",[90],"2015-08","2013-05",[2954,2955],"Epilepsy","Drug Hypersensitivity Syndrome",[2957,2751],"anti-epileptic drug",{"nctId":2959,"briefTitle":2960,"status":144,"phases":2961,"primaryCompletion":1014,"completion":1014,"start":2962,"enrollment":2963,"conditions":2964,"interventions":2966},"NCT02556281","Prognostic Value of Circulating Tumoral Free DNA Versus Circulating Tumoral Cells in Patients With Colorectal Cancer Stage II-III",[90],"2012-10-15",216,[2965],"Colorectal Neoplasms",[2751],{"intervention":2968,"totalTrials":93,"cells":2969},"neoadjuvant chemotherapy with cisplatine",{"EARLY_PHASE1":2970,"PHASE1":2972,"PHASE2":2974,"PHASE3":2976,"PHASE4":2978,"NA":2980},{"trials":2971,"activeCount":97},[],{"trials":2973,"activeCount":97},[],{"trials":2975,"activeCount":97},[],{"trials":2977,"activeCount":97},[],{"trials":2979,"activeCount":97},[],{"trials":2981,"activeCount":97},[2982,2992],{"nctId":2983,"briefTitle":2984,"status":144,"phases":2985,"primaryCompletion":2986,"completion":2986,"start":2987,"enrollment":2988,"conditions":2989,"interventions":2991},"NCT04089748","Basal Tumours in Bladder Cancer, Response to chemoTherapy",[],"2019-04-29","2019-02-27",293,[2055,2990],"Chemotherapy Effect",[2968],{"nctId":2993,"briefTitle":2994,"status":1857,"phases":2995,"primaryCompletion":2996,"completion":2996,"start":2997,"enrollment":2998,"conditions":2999,"interventions":3001},"NCT06294054","Bladder Cancer and Neoadjuvant Chemotherapy Efficiency Before Cystectomy",[],"2026-03-31","2023-04-01",707,[2055,3000],"Genomic Instability",[2968],{"intervention":3003,"totalTrials":93,"cells":3004},"Blood samples",{"EARLY_PHASE1":3005,"PHASE1":3007,"PHASE2":3009,"PHASE3":3011,"PHASE4":3013,"NA":3015},{"trials":3006,"activeCount":97},[],{"trials":3008,"activeCount":97},[],{"trials":3010,"activeCount":97},[],{"trials":3012,"activeCount":97},[],{"trials":3014,"activeCount":97},[],{"trials":3016,"activeCount":97},[3017,3026],{"nctId":3018,"briefTitle":3019,"status":144,"phases":3020,"primaryCompletion":3021,"completion":3021,"start":3022,"enrollment":1021,"conditions":3023,"interventions":3025},"NCT03721809","Characterization of the Inflammatory Profile of Patients With Macrophage Activation Syndrome Secondary to Bacterial Sepsis",[90],"2023-02-08","2019-03-21",[3024],"Macrophage Activation Syndrome",[3003],{"nctId":3027,"briefTitle":3028,"status":144,"phases":3029,"primaryCompletion":168,"completion":168,"start":3030,"enrollment":3031,"conditions":3032,"interventions":3034},"NCT02311075","Mechanisms of Endothelial Dysfunction in Type 2 Diabetes",[90],"2014-12",48,[3033],"Diabetes Mellitus, Type 2",[3003],{"intervention":3036,"totalTrials":93,"cells":3037},"MenBvac",{"EARLY_PHASE1":3038,"PHASE1":3040,"PHASE2":3042,"PHASE3":3044,"PHASE4":3056,"NA":3058},{"trials":3039,"activeCount":97},[],{"trials":3041,"activeCount":97},[],{"trials":3043,"activeCount":97},[],{"trials":3045,"activeCount":97},[3046],{"nctId":3047,"briefTitle":3048,"status":144,"phases":3049,"primaryCompletion":158,"completion":2530,"start":3050,"enrollment":3051,"conditions":3052,"interventions":3054},"NCT01565577","Evaluation of Immune Response Against the Strain of Neisseria Meningitidis B: 14, P1-7, 16 Patients Vaccinated With MenBVac® (Extension MenbVac)",[88],"2012-04",117,[3053],"Vaccination With MenbVac",[3055],"MenbVac",{"trials":3057,"activeCount":97},[],{"trials":3059,"activeCount":97},[3060],{"nctId":3061,"briefTitle":3062,"status":144,"phases":3063,"primaryCompletion":3064,"completion":3065,"start":3050,"enrollment":827,"conditions":3066,"interventions":3068},"NCT01621945","Evaluation of Immune Response Against the Strain of Neisseria Meningitidis B: 14, P1-7, 16 in Patients Having to be Vaccinated MenBVac® (Extension EFFIVAC)",[],"2013-04","2013-09",[3067],"Neisseria Meningitidis",[3036],{"intervention":3070,"totalTrials":93,"cells":3071},"Blood drawn",{"EARLY_PHASE1":3072,"PHASE1":3074,"PHASE2":3076,"PHASE3":3078,"PHASE4":3080,"NA":3082},{"trials":3073,"activeCount":97},[],{"trials":3075,"activeCount":97},[],{"trials":3077,"activeCount":97},[],{"trials":3079,"activeCount":97},[],{"trials":3081,"activeCount":97},[],{"trials":3083,"activeCount":97},[3084,3093],{"nctId":3085,"briefTitle":3086,"status":144,"phases":3087,"primaryCompletion":1531,"completion":1531,"start":3088,"enrollment":3089,"conditions":3090,"interventions":3092},"NCT02570464","Aortic Cross-Clamping and Systemic Inflammatory Response in Humans: Effect of Ischemic Preconditioning",[90],"2012-03",68,[3091],"Aortic Aneurysm",[3070],{"nctId":3094,"briefTitle":3095,"status":144,"phases":3096,"primaryCompletion":1814,"completion":1814,"start":3097,"enrollment":3098,"conditions":3099,"interventions":3101},"NCT01057953","Oligogenic Determinism of Colorectal Cancer",[90],"2010-01",1550,[3100],"Cancer",[3070],{"intervention":3103,"totalTrials":118,"cells":3104},"Pre-treatment with octreotide",{"EARLY_PHASE1":3105,"PHASE1":3107,"PHASE2":3109,"PHASE3":3111,"PHASE4":3113,"NA":3115},{"trials":3106,"activeCount":97},[],{"trials":3108,"activeCount":97},[],{"trials":3110,"activeCount":97},[],{"trials":3112,"activeCount":97},[],{"trials":3114,"activeCount":97},[],{"trials":3116,"activeCount":97},[3117],{"nctId":3118,"briefTitle":3119,"status":144,"phases":3120,"primaryCompletion":3121,"completion":3121,"start":3122,"enrollment":3123,"conditions":3124,"interventions":3126},"NCT01029275","Somatostatin Analog Treatment of Acromegaly Before Pituitary Surgery : Comparison With Neurosurgery Alone",[90],"2012-01","2005-01",89,[3125],"Acromegaly",[3103],{"intervention":3128,"totalTrials":118,"cells":3129},"Genetic-Tailored AntiThrombotic Strategy",{"EARLY_PHASE1":3130,"PHASE1":3132,"PHASE2":3134,"PHASE3":3136,"PHASE4":3138,"NA":3140},{"trials":3131,"activeCount":97},[],{"trials":3133,"activeCount":97},[],{"trials":3135,"activeCount":97},[],{"trials":3137,"activeCount":97},[],{"trials":3139,"activeCount":97},[],{"trials":3141,"activeCount":97},[3142],{"nctId":3143,"briefTitle":3144,"status":144,"phases":3145,"primaryCompletion":3146,"completion":3146,"start":3147,"enrollment":3148,"conditions":3149,"interventions":3151},"NCT01622894","Genetics of Mendelian Forms of Young Onset Alzheimer Disease",[90],"2018-12-15","2009-11-15",150,[3150],"Autosomal Dominant Cases of Alzheimer 's Disease",[3128],{"intervention":3153,"totalTrials":118,"cells":3154},"SNP Genotyping",{"EARLY_PHASE1":3155,"PHASE1":3157,"PHASE2":3159,"PHASE3":3161,"PHASE4":3163,"NA":3165},{"trials":3156,"activeCount":97},[],{"trials":3158,"activeCount":97},[],{"trials":3160,"activeCount":97},[],{"trials":3162,"activeCount":97},[],{"trials":3164,"activeCount":97},[],{"trials":3166,"activeCount":97},[3167],{"nctId":3168,"briefTitle":3169,"status":144,"phases":3170,"primaryCompletion":1459,"completion":1459,"start":167,"enrollment":3171,"conditions":3172,"interventions":3174},"NCT02001649","Genetic Variants Associated With Adolescent Suicide Attempts",[90],250,[3173],"Attempt Suicide",[3153,3175],"SNP genotyping",{"intervention":3177,"totalTrials":118,"cells":3178},"bladder tumor recurrence",{"EARLY_PHASE1":3179,"PHASE1":3181,"PHASE2":3183,"PHASE3":3185,"PHASE4":3187,"NA":3189},{"trials":3180,"activeCount":97},[],{"trials":3182,"activeCount":97},[],{"trials":3184,"activeCount":97},[],{"trials":3186,"activeCount":97},[],{"trials":3188,"activeCount":97},[],{"trials":3190,"activeCount":97},[3191],{"nctId":3192,"briefTitle":3193,"status":144,"phases":3194,"primaryCompletion":2952,"completion":167,"start":3195,"enrollment":3196,"conditions":3197,"interventions":3198},"NCT00213655","URO-BCG-4 : Bladder Tumors Immunotherapy",[],"2004-06",146,[2055],[3177],{"intervention":3200,"totalTrials":118,"cells":3201},"pipéracilline\u002Ftazobactam",{"EARLY_PHASE1":3202,"PHASE1":3204,"PHASE2":3206,"PHASE3":3208,"PHASE4":3210,"NA":3212},{"trials":3203,"activeCount":97},[],{"trials":3205,"activeCount":97},[],{"trials":3207,"activeCount":97},[],{"trials":3209,"activeCount":97},[],{"trials":3211,"activeCount":97},[],{"trials":3213,"activeCount":97},[3214],{"nctId":3215,"briefTitle":3216,"status":1857,"phases":3217,"primaryCompletion":3218,"completion":3219,"start":3220,"enrollment":170,"conditions":3221,"interventions":3223},"NCT03748095","Population Pharmacokinetic Modeling to Optimize the Dosage of the Piperacillin \u002F Tazobactam Combination in Patients With Sepsis in Intensive Care",[],"2023-03-15","2024-06-15","2019-03-12",[3222],"Resuscitation Patients With Sepsis",[3200],{"intervention":3225,"totalTrials":118,"cells":3226},"free ceftriaxone concentration dosage",{"EARLY_PHASE1":3227,"PHASE1":3229,"PHASE2":3231,"PHASE3":3233,"PHASE4":3235,"NA":3237},{"trials":3228,"activeCount":97},[],{"trials":3230,"activeCount":97},[],{"trials":3232,"activeCount":97},[],{"trials":3234,"activeCount":97},[],{"trials":3236,"activeCount":97},[],{"trials":3238,"activeCount":97},[3239],{"nctId":3240,"briefTitle":3241,"status":995,"phases":3242,"primaryCompletion":3243,"completion":3244,"start":3245,"enrollment":803,"conditions":3246,"interventions":3248},"NCT07169097","Study of the Pharmacokinetics of Ceftriaxone",[],"2025-11-30","2025-12-30","2024-09-30",[3247],"Urinary Infections",[3225],{"intervention":3250,"totalTrials":118,"cells":3251},"docetaxel and celecoxib",{"EARLY_PHASE1":3252,"PHASE1":3254,"PHASE2":3256,"PHASE3":3258,"PHASE4":3260,"NA":3262},{"trials":3253,"activeCount":97},[],{"trials":3255,"activeCount":97},[],{"trials":3257,"activeCount":97},[],{"trials":3259,"activeCount":97},[],{"trials":3261,"activeCount":97},[],{"trials":3263,"activeCount":97},[3264],{"nctId":3265,"briefTitle":3266,"status":144,"phases":3267,"completion":1675,"start":3268,"enrollment":3269,"conditions":3270,"interventions":3272},"NCT00213694","PROSTACOX : Metastatic Prostate Chemotherapy",[],"2003-11",52,[3271],"Metastatic Prostate Cancer",[3250],{"intervention":3274,"totalTrials":118,"cells":3275},"response to infliximab associated with methotrexate",{"EARLY_PHASE1":3276,"PHASE1":3278,"PHASE2":3280,"PHASE3":3282,"PHASE4":3284,"NA":3286},{"trials":3277,"activeCount":97},[],{"trials":3279,"activeCount":97},[],{"trials":3281,"activeCount":97},[],{"trials":3283,"activeCount":97},[],{"trials":3285,"activeCount":97},[],{"trials":3287,"activeCount":97},[3288],{"nctId":3289,"briefTitle":3290,"status":144,"phases":3291,"primaryCompletion":3292,"completion":998,"start":3293,"enrollment":1532,"conditions":3294,"interventions":3295},"NCT00213564","Gene Expression Profiling in PBMCs as a Tool for Prediction of Infliximab Responsiveness in Rheumatoid Arthritis",[],"2004-05","2003-04",[29],[3274],{"intervention":3297,"totalTrials":118,"cells":3298},"evaluation of the recurrence rate according to molecular analysis",{"EARLY_PHASE1":3299,"PHASE1":3301,"PHASE2":3303,"PHASE3":3305,"PHASE4":3307,"NA":3309},{"trials":3300,"activeCount":97},[],{"trials":3302,"activeCount":97},[],{"trials":3304,"activeCount":97},[],{"trials":3306,"activeCount":97},[],{"trials":3308,"activeCount":97},[],{"trials":3310,"activeCount":97},[3311],{"nctId":3312,"briefTitle":3313,"status":144,"phases":3314,"primaryCompletion":3315,"completion":3316,"start":3317,"enrollment":3318,"conditions":3319,"interventions":3321},"NCT02110329","Simultaneaous Detection of Quantitative Somatic Alterations Using the Qantitative Multiplex Pcr of Short Fluorescent Fragments Method (QMPSF) in Stage II-III Colon Cancer: a Prospective Study",[90],"2013-06","2013-11","2010-05",401,[632,3320],"Stage II and III",[3297],{"intervention":3323,"totalTrials":118,"cells":3324},"PTP1B dosage",{"EARLY_PHASE1":3325,"PHASE1":3327,"PHASE2":3329,"PHASE3":3331,"PHASE4":3333,"NA":3335},{"trials":3326,"activeCount":97},[],{"trials":3328,"activeCount":97},[],{"trials":3330,"activeCount":97},[],{"trials":3332,"activeCount":97},[],{"trials":3334,"activeCount":97},[],{"trials":3336,"activeCount":97},[3337],{"nctId":3338,"briefTitle":3339,"status":144,"phases":3340,"primaryCompletion":3341,"completion":3341,"start":3342,"enrollment":3343,"conditions":3344,"interventions":3345},"NCT02295514","Correlation Between PTP1B Expression and Organ Failure During Sepsis",[90],"2016-05","2015-01",54,[1182],[3323],{"intervention":3347,"totalTrials":118,"cells":3348},"Dermoval",{"EARLY_PHASE1":3349,"PHASE1":3351,"PHASE2":3353,"PHASE3":3355,"PHASE4":3357,"NA":3359},{"trials":3350,"activeCount":97},[],{"trials":3352,"activeCount":97},[],{"trials":3354,"activeCount":97},[],{"trials":3356,"activeCount":97},[],{"trials":3358,"activeCount":97},[],{"trials":3360,"activeCount":97},[3361],{"nctId":3362,"briefTitle":3363,"status":144,"phases":3364,"primaryCompletion":3365,"completion":3366,"start":3367,"enrollment":3368,"conditions":3369,"interventions":3370},"NCT00213421","Comparison of Two Therapeutic Strategies of Dermoval in Treatment of Bullous Pemphigus",[],"2004-10","2008-11","2001-08",330,[1413],[3347],{"intervention":3372,"totalTrials":118,"cells":3373},"Genetic analysis",{"EARLY_PHASE1":3374,"PHASE1":3376,"PHASE2":3378,"PHASE3":3380,"PHASE4":3382,"NA":3384},{"trials":3375,"activeCount":97},[],{"trials":3377,"activeCount":97},[],{"trials":3379,"activeCount":97},[],{"trials":3381,"activeCount":97},[],{"trials":3383,"activeCount":97},[],{"trials":3385,"activeCount":97},[3386],{"nctId":3387,"briefTitle":3388,"status":995,"phases":3389,"primaryCompletion":3390,"completion":3390,"start":3391,"enrollment":3392,"conditions":3393,"interventions":3398},"NCT02664389","Targeted Next-generation Sequencing Panel for Identification of Germline Mutations in Early Onset Cancers With Sporadic or Hereditary Presentation",[90],"2017-03-15","2016-02-01",289,[3394,3395,632,3396,3397],"Breast Cancer","Ovarian Cancer","Pediatric Cancers","Multiple Primary Malignant Tumours",[3372],{"intervention":3400,"totalTrials":118,"cells":3401},"gadobenic acid intravenous injection 0.2 ml\u002Fkg",{"EARLY_PHASE1":3402,"PHASE1":3404,"PHASE2":3406,"PHASE3":3408,"PHASE4":3410,"NA":3412},{"trials":3403,"activeCount":97},[],{"trials":3405,"activeCount":97},[],{"trials":3407,"activeCount":97},[],{"trials":3409,"activeCount":97},[],{"trials":3411,"activeCount":97},[],{"trials":3413,"activeCount":97},[3414],{"nctId":3415,"briefTitle":3416,"status":3417,"phases":3418,"primaryCompletion":3419,"completion":3420,"start":3342,"enrollment":97,"conditions":3421,"interventions":3423},"NCT02400840","Acute Heart Graft Rejection Screening by Cardiac Magnetic Resonance Imaging","WITHDRAWN",[90],"2018-01","2018-05",[3422],"Cardiac Graft",[3400],{"intervention":3425,"totalTrials":118,"cells":3426},"Desensitization protocol",{"EARLY_PHASE1":3427,"PHASE1":3429,"PHASE2":3431,"PHASE3":3433,"PHASE4":3435,"NA":3437},{"trials":3428,"activeCount":97},[],{"trials":3430,"activeCount":97},[],{"trials":3432,"activeCount":97},[],{"trials":3434,"activeCount":97},[],{"trials":3436,"activeCount":97},[],{"trials":3438,"activeCount":97},[3439],{"nctId":3440,"briefTitle":3441,"status":144,"phases":3442,"primaryCompletion":3443,"completion":3443,"start":3444,"enrollment":3445,"conditions":3446,"interventions":3448},"NCT02295488","Determinism of the Mechanism of Action of Specific Immunotherapy in Hymenoptera Venom Allergy",[90],"2018-04-12","2015-03-23",29,[3447],"Hymenoptera Allergy",[3425],{"intervention":3450,"totalTrials":118,"cells":3451},"genome-wide analyses",{"EARLY_PHASE1":3452,"PHASE1":3454,"PHASE2":3456,"PHASE3":3458,"PHASE4":3460,"NA":3462},{"trials":3453,"activeCount":97},[],{"trials":3455,"activeCount":97},[],{"trials":3457,"activeCount":97},[],{"trials":3459,"activeCount":97},[],{"trials":3461,"activeCount":97},[],{"trials":3463,"activeCount":97},[3464],{"nctId":3465,"briefTitle":3466,"status":144,"phases":3467,"primaryCompletion":3468,"completion":3468,"start":3469,"enrollment":32,"conditions":3470,"interventions":3472},"NCT04564235","Risk of Recurrence of de Novo Mutations: Research and Quantification of Paternal Germinal Mosaicism by the Combined Use of Genomic Tools",[90],"2022-12-12","2021-02-24",[3471],"Developmental Disorders",[3450,3473],"Search for de novo mutations in paternal sperm samples",{"intervention":3473,"totalTrials":118,"cells":3475},{"EARLY_PHASE1":3476,"PHASE1":3478,"PHASE2":3480,"PHASE3":3482,"PHASE4":3484,"NA":3486},{"trials":3477,"activeCount":97},[],{"trials":3479,"activeCount":97},[],{"trials":3481,"activeCount":97},[],{"trials":3483,"activeCount":97},[],{"trials":3485,"activeCount":97},[],{"trials":3487,"activeCount":97},[3488],{"nctId":3465,"briefTitle":3466,"status":144,"phases":3489,"primaryCompletion":3468,"completion":3468,"start":3469,"enrollment":32,"conditions":3490,"interventions":3491},[90],[3471],[3450,3473],{"intervention":3493,"totalTrials":118,"cells":3494},"Response to anakinra associated with methotrexate",{"EARLY_PHASE1":3495,"PHASE1":3497,"PHASE2":3499,"PHASE3":3501,"PHASE4":3503,"NA":3505},{"trials":3496,"activeCount":97},[],{"trials":3498,"activeCount":97},[],{"trials":3500,"activeCount":97},[],{"trials":3502,"activeCount":97},[],{"trials":3504,"activeCount":97},[],{"trials":3506,"activeCount":97},[3507],{"nctId":3508,"briefTitle":3509,"status":144,"phases":3510,"primaryCompletion":168,"completion":168,"start":1677,"enrollment":3511,"conditions":3512,"interventions":3513},"NCT00213538","Gene Expression Profiling in PBMCs as a Tool for Prediction of Anakinra Responsiveness in Rheumatoid Arthritis",[],341,[29],[3493],{"intervention":2957,"totalTrials":118,"cells":3515},{"EARLY_PHASE1":3516,"PHASE1":3518,"PHASE2":3520,"PHASE3":3522,"PHASE4":3524,"NA":3526},{"trials":3517,"activeCount":97},[],{"trials":3519,"activeCount":97},[],{"trials":3521,"activeCount":97},[],{"trials":3523,"activeCount":97},[],{"trials":3525,"activeCount":97},[],{"trials":3527,"activeCount":97},[3528],{"nctId":2948,"briefTitle":2949,"status":144,"phases":3529,"primaryCompletion":2951,"completion":1531,"start":2952,"enrollment":195,"conditions":3530,"interventions":3531},[90],[2954,2955],[2957,2751],{"intervention":3533,"totalTrials":118,"cells":3534},"Medical drainage",{"EARLY_PHASE1":3535,"PHASE1":3537,"PHASE2":3539,"PHASE3":3541,"PHASE4":3543,"NA":3545},{"trials":3536,"activeCount":97},[],{"trials":3538,"activeCount":97},[],{"trials":3540,"activeCount":97},[],{"trials":3542,"activeCount":97},[],{"trials":3544,"activeCount":97},[],{"trials":3546,"activeCount":97},[3547],{"nctId":3548,"briefTitle":3549,"status":144,"phases":3550,"primaryCompletion":3551,"completion":3551,"start":3552,"enrollment":11,"conditions":3553,"interventions":3555},"NCT01994499","Randomized Study Comparing Pleural Drainage by Videothoracoscopy to Medical Drainage in Infectious Pleural Effusion",[90],"2019-07-12","2014-01-24",[3554],"Infectious Pleural Effusion",[3533],{"intervention":3557,"totalTrials":118,"cells":3558},"Enzyme replacement therapy",{"EARLY_PHASE1":3559,"PHASE1":3561,"PHASE2":3563,"PHASE3":3565,"PHASE4":3567,"NA":3569},{"trials":3560,"activeCount":97},[],{"trials":3562,"activeCount":97},[],{"trials":3564,"activeCount":97},[],{"trials":3566,"activeCount":97},[],{"trials":3568,"activeCount":97},[],{"trials":3570,"activeCount":97},[3571],{"nctId":3572,"briefTitle":3573,"status":144,"phases":3574,"primaryCompletion":3575,"completion":3575,"start":3576,"enrollment":3577,"conditions":3578,"interventions":3580},"NCT02956954","Follow-up of Myocardial T1 Relaxation Time in Patients With Anderson Fabry Disease",[90],"2023-01-23","2017-03-25",26,[3579],"Anderson-Fabry Disease",[3557],{"intervention":3582,"totalTrials":118,"cells":3583},"Determination of the clinical and biological characteristics",{"EARLY_PHASE1":3584,"PHASE1":3586,"PHASE2":3588,"PHASE3":3590,"PHASE4":3592,"NA":3594},{"trials":3585,"activeCount":97},[],{"trials":3587,"activeCount":97},[],{"trials":3589,"activeCount":97},[],{"trials":3591,"activeCount":97},[],{"trials":3593,"activeCount":97},[],{"trials":3595,"activeCount":97},[3596],{"nctId":3597,"briefTitle":3598,"status":1857,"phases":3599,"primaryCompletion":3600,"completion":3600,"start":3601,"enrollment":1134,"conditions":3602,"interventions":3604},"NCT04318262","Burden of Staphylococcus Lugdunensis Infections in Hospitalized Patients",[],"2022-12","2020-09",[3603],"Staphylococcus Lugdunensis Infection",[3582,3605,3606],"Description of the antibiotic resistance profile","Molecular epidemiology of S. lugdunensis infections",{"intervention":3605,"totalTrials":118,"cells":3608},{"EARLY_PHASE1":3609,"PHASE1":3611,"PHASE2":3613,"PHASE3":3615,"PHASE4":3617,"NA":3619},{"trials":3610,"activeCount":97},[],{"trials":3612,"activeCount":97},[],{"trials":3614,"activeCount":97},[],{"trials":3616,"activeCount":97},[],{"trials":3618,"activeCount":97},[],{"trials":3620,"activeCount":97},[3621],{"nctId":3597,"briefTitle":3598,"status":1857,"phases":3622,"primaryCompletion":3600,"completion":3600,"start":3601,"enrollment":1134,"conditions":3623,"interventions":3624},[],[3603],[3582,3605,3606],{"intervention":3606,"totalTrials":118,"cells":3626},{"EARLY_PHASE1":3627,"PHASE1":3629,"PHASE2":3631,"PHASE3":3633,"PHASE4":3635,"NA":3637},{"trials":3628,"activeCount":97},[],{"trials":3630,"activeCount":97},[],{"trials":3632,"activeCount":97},[],{"trials":3634,"activeCount":97},[],{"trials":3636,"activeCount":97},[],{"trials":3638,"activeCount":97},[3639],{"nctId":3597,"briefTitle":3598,"status":1857,"phases":3640,"primaryCompletion":3600,"completion":3600,"start":3601,"enrollment":1134,"conditions":3641,"interventions":3642},[],[3603],[3582,3605,3606],{"intervention":3644,"totalTrials":118,"cells":3645},"DNA",{"EARLY_PHASE1":3646,"PHASE1":3648,"PHASE2":3650,"PHASE3":3652,"PHASE4":3654,"NA":3656},{"trials":3647,"activeCount":97},[],{"trials":3649,"activeCount":97},[],{"trials":3651,"activeCount":97},[],{"trials":3653,"activeCount":97},[],{"trials":3655,"activeCount":97},[],{"trials":3657,"activeCount":97},[3658],{"nctId":3659,"briefTitle":3660,"status":1857,"phases":3661,"primaryCompletion":3662,"completion":3663,"start":3664,"enrollment":3665,"conditions":3666,"interventions":3670},"NCT05390112","Cohort Study of Patients With Hepatocellular Carcinoma and Circulating Tumor DNA Monitoring of Chemoembolization",[],"2024-06-30","2024-12-31","2021-05-20",167,[3667,3668,3669],"Circulating Tumor DNA","Hepatocellular Carcinoma Non-resectable","Transarterial Chemoembolization",[3644],{"intervention":3672,"totalTrials":118,"cells":3673},"BQ-788 and\u002For BQ-123",{"EARLY_PHASE1":3674,"PHASE1":3676,"PHASE2":3678,"PHASE3":3680,"PHASE4":3682,"NA":3684},{"trials":3675,"activeCount":97},[],{"trials":3677,"activeCount":97},[],{"trials":3679,"activeCount":97},[],{"trials":3681,"activeCount":97},[],{"trials":3683,"activeCount":97},[],{"trials":3685,"activeCount":97},[3686],{"nctId":3687,"briefTitle":3688,"status":144,"phases":3689,"primaryCompletion":1301,"completion":1301,"start":2096,"enrollment":19,"conditions":3690,"interventions":3692},"NCT02086253","Role of Endothelin-1 in Flow-mediated Dilatation",[90],[3691],"Healthy Conditions",[3672]]